SalemExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	23.34	35	150 #+	Male	15.66	14	89
Female	10.88	5	46	Female	13.98	16	114
Total	34.21	40	117	Total	29.64	30	101
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	7.01	5	71	Male	4.48	3	NC*
Female	6.53	5	77	Female	4.74	5	105
Total	13.53	10	74	Total	9.22	8	87
<u>Breast</u>				Non-Hodgkin('s) Ly	mphoma		
Male	1.08	1	NC*	Male	19.07	23	121
Female	162.27	174	107	Female	20.29	19	94
Total	163.35	175	107	Total	39.36	42	107
Cervix Uteri				Oral Cavity and Pha	<u>arynx</u>		
				Male	14.10	26	184 ~+
Female	9.53	6	63	Female	8.19	14	171
				Total	22.29	40	179 ^+
Colon / Rectum				<u>Ovary</u>			
Male	57.79	55	95				
Female	68.64	74	108	Female	19.04	29	152 #+
Total	126.43	129	102				
Esophagus				<u>Pancreas</u>			
Male	8.10	13	161	Male	9.66	10	103
Female	3.33	5	150	Female	12.51	12	96
Total	11.43	18	157	Total	22.17	22	99
Hodgkin's Disease				Prostate			
Male	3.84		182	Male	139.55	184	132 ^+
Female	3.38	5	148				
Total	7.22	12	166				
Kidney and Renal P				Stomach			
Male	13.44	16	119	Male	9.81	8	82
Female	9.98	12	120	Female	7.51	6	80
Total	23.42	28	120	Total	17.32	14	81
<u>Larynx</u>	20.12	20	.20	<u>Testis</u>	17.02		•
Male	7.53	6	80	Male	6.28	8	127
Female	2.20	2	NC*	maio	0.20	· ·	
Total	9.73	8	82				
Leukemia	3.70	J	02	<u>Thyroid</u>			
Male	11.03	14	127	Male	3.23	6	186
Female	10.13	13	128	Female	9.81	6	61
Total	21.15	27	128	Total	13.04	12	92
Liver and Intrahepa		21	120	Uteri, Corpus and U		12	32
Male	5.20	3	NC*	oten, corpus and o	iterus, NOS		
Female	2.70	3 1	NC*	Female	30.78	37	120
				remale	30.70	31	120
Total	7.90	4	NC*	All Cites / Tomas			
Lung and Bronchus	_	OG	400	All Sites / Types	161 69	ECC	100 A .
Male	72.26	96 103	133 ~+	Male	464.68	566 580	122 ^+
Female	68.55	102	149 ^+	Female	524.44	589	112 ~+
Total	140.81	198	141 ^+	Total	989.12	1155	117 ^+

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Salisbury
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	4.23	2	NC*	Male	3.02	5	165
Female	1.59	0	NC*	Female	2.31	5	216
Total	5.82	2	NC*	Total	5.33	10	187
Brain and Other Ce	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	1.39	1	NC*	Male	0.86	1	NC*
Female	1.10	1	NC*	Female	0.74	1	NC*
Total	2.49	2	NC*	Total	1.60	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Male	0.21	0	NC*	Male	3.61	2	NC*
Female	27.72	30	108	Female	3.16	4	NC*
Total	27.92	30	107	Total	6.77	6	89
Cervix Uteri				Oral Cavity and Phan	rynx		
				Male	2.88	3	NC*
Female	1.61	3	NC*	Female	1.34	2	NC*
				Total	4.22	5	118
Colon / Rectum				<u>Ovary</u>			
Male	10.59	19	179 #+				
Female	9.94	13	131	Female	3.24	2	NC*
Total	20.53	32	156 #+				
Esophagus				<u>Pancreas</u>			
Male	1.61	4	NC*	Male	1.82	1	NC*
Female	0.48	0	NC*	Female	1.85	4	NC*
Total	2.09	4	NC*	Total	3.67	5	136
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	0.70	2	NC*	Male	27.26	31	114
Female	0.54	0	NC*				
Total	1.25	2	NC*				
Kidney and Renal F	<u>Pelvis</u>			<u>Stomach</u>			
Male	2.67	1	NC*	Male	1.81	0	NC*
Female	1.64	4	NC*	Female	1.07	2	NC*
Total	4.31	5	116	Total	2.88	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.53	4	NC*	Male	1.07	3	NC*
Female	0.39	0	NC*				
Total	1.92	4	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.09	1	NC*	Male	0.63	1	NC*

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Female	1.63	2	NC*	Female	1.65	2	NC*	
Total	3.72	3	NC*	Total	2.28	3	NC*	
Liver and Intrahe	epatic Bile Ducts			Uteri, Corpus and Uterus, NOS				
Male	1.03	0	NC*					
Female	0.41	0	NC*	Female	5.38	9	167	
Total	1.44	0	NC*					
Lung and Bronc	<u>hus</u>			All Sites / Types				
Male	13.79	18	131	Male	88.71	108	122	
Female	11.18	16	143	Female	84.89	104	123 #+	
Total	24.97	34	136	Total	173.60	212	122 ~+	

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

SandisfieldExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	0.78	1	NC*	Male	0.48	0	NC*
Female	0.20	0	NC*	Female	0.25	0	NC*
Total	0.98	1	NC*	Total	0.73	0	NC*
Brain and Other C	entral Nervous Sy	<u>/stem</u>		Multiple Myeloma			
Male	0.21	0	NC*	Male	0.15	0	NC*
Female	0.12	0	NC*	Female	0.09	1	NC*
Total	0.33	0	NC*	Total	0.24	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>iphoma</u>		
Male	0.04	0	NC*	Male	0.58	2	NC*
Female	3.12	4	NC*	Female	0.38	0	NC*
Total	3.16	4	NC*	Total	0.95	2	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	0.47	0	NC*
Female	0.16	0	NC*	Female	0.16	1	NC*
				Total	0.63	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	1.95	0	NC*				
Female	1.24	0	NC*	Female	0.36	1	NC*
Total	3.19	0	NC*				
Esophagus				<u>Pancreas</u>			
Male	0.29	2	NC*	Male	0.33	0	NC*
Female	0.06	0	NC*	Female	0.24	0	NC*
Total	0.35	2	NC*	Total	0.56	0	NC*
Hodgkin's Disease		<u>noma)</u>		<u>Prostate</u>			
Male	0.08	0	NC*	Male	5.24	1	NC*
Female	0.05	0	NC*				

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Total	0.14	0	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	0.45	0	NC*	Male	0.32	0	NC*
Female	0.20	0	NC*	Female	0.13	0	NC*
Total	0.64	0	NC*	Total	0.45	0	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.27	1	NC*	Male	0.11	0	NC*
Female	0.05	0	NC*				
Total	0.32	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.34	0	NC*	Male	0.09	0	NC*
Female	0.18	0	NC*	Female	0.16	0	NC*
Total	0.52	0	NC*	Total	0.24	0	NC*
Liver and Intrahepat	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	0.18	0	NC*				
Female	0.05	0	NC*	Female	0.62	1	NC*
Total	0.23	0	NC*				
Lung and Bronchus	<u>i</u>			All Sites / Types			
Male	2.59	0	NC*	Male	15.91	7	44 #-
Female	1.39	0	NC*	Female	9.90	9	91
Total	3.98	0	NC*	Total	25.81	16	62

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Sandwich
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	14.48	16	110	Male	9.16	15	164
Female	5.09	9	177	Female	6.55	9	137
Total	19.57	25	128	Total	15.71	24	153
Brain and Other Cer	ntral Nervous S	<u>system</u>		Multiple Myeloma			
Male	4.01	2	NC*	Male	2.80	2	NC*
Female	3.16	3	NC*	Female	2.32	1	NC*
Total	7.18	5	70	Total	5.12	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>iphoma</u>		
Male	0.67	0	NC*	Male	11.12	6	54
Female	80.86	89	110	Female	9.63	5	52
Total	81.53	89	109	Total	20.75	11	53 #-
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	8.69	8	92
Female	4.30	5	116	Female	4.03	4	NC*
				Total	12.71	12	94

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Colon / Rectum				<u>Ovary</u>			
Male	35.73	38	106				
Female	31.97	29	91	Female	9.35	8	86
Total	67.70	67	99				
Esophagus				<u>Pancreas</u>			
Male	5.09	4	NC*	Male	6.00	3	NC*
Female	1.56	3	NC*	Female	5.90	4	NC*
Total	6.64	7	105	Total	11.90	7	59
Hodgkin's Disease	(Hodgkin Lympl	noma)		Prostate			
Male	1.83	0	NC*	Male	88.06	93	106
Female	1.41	0	NC*				
Total	3.25	0	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	8.28	6	72	Male	6.06	7	116
Female	4.93	7	142	Female	3.42	2	NC*
Total	13.21	13	98	Total	9.48	9	95
<u>Larynx</u>				<u>Testis</u>			
Male	4.73	3	NC*	Male	2.52	1	NC*
Female	1.15	1	NC*				
Total	5.88	4	NC*				
<u>Leukemia</u>				Thyroid			
Male	6.61	9	136	Male	1.69	2	NC*
Female	4.87	8	164	Female	4.28	7	163
Total	11.48	17	148	Total	5.97	9	151
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	3.21	1	NC*				
Female	1.29	1	NC*	Female	15.87	13	82
Total	4.50	2	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	45.08	24	53 ^-	Male	284.94	265	93
Female	34.29	30	87	Female	254.70	258	101
Total	79.38	54	68 ~ -	Total	539.64	523	97

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

SaugusExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	18.88	27	143	Male	12.22	12	98
Female	7.50	8	107	Female	9.50	9	95
Total	26.39	35	133	Total	21.72	21	97
Brain and Other Ce	entral Nervous	<u>System</u>		Multiple Myeloma			

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Male	5.35	8	149	Male	3.68	4	NC*
Female	4.47	3	NC*	Female	3.37	4	NC*
Total	9.82	11	112	Total	7.05	8	113
<u>Breast</u>				Non-Hodgkin('s) Ly	<u>mphoma</u>		
Male	0.89	3	NC*	Male	14.75	17	115
Female	116.68	112	96	Female	14.02	14	100
Total	117.57	115	98	Total	28.76	31	108
Cervix Uteri				Oral Cavity and Pha	<u>arynx</u>		
				Male	11.50	12	104
Female	6.26	5	80	Female	5.83	8	137
				Total	17.34	20	115
Colon / Rectum				<u>Ovary</u>			
Male	46.90	50	107				
Female	47.06	58	123	Female	13.48	10	74
Total	93.96	108	115				
Esophagus				<u>Pancreas</u>			
Male	6.73	6	89	Male	7.88	17	216 ~+
Female	2.30	1	NC*	Female	8.69	8	92
Total	9.02	7	78	Total	16.57	25	151
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		Prostate			
Male	2.55	0	NC*	Male	118.04	140	119
Female	2.04	3	NC*				
Total	4.59	3	NC*				
Kidney and Renal I	<u>Pelvis</u>			Stomach .			
Male	10.96	16	146	Male	7.87	11	140
Female	7.14	10	140	Female	5.07	6	118
Total	18.10	26	144	Total	12.94	17	131
<u>Larynx</u>				<u>Testis</u>			
Male	6.31	4	NC*	Male	3.74	5	134
Female	1.65	2	NC*				
Total	7.96	6	75				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	8.60	15	174	Male	2.33	4	NC*
Female	6.94	8	115	Female	6.23	10	161
Total	15.55	23	148	Total	8.56	14	164
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and L	<u>Jterus, NOS</u>		
Male	4.26	10	235 #+				
Female	1.89	3	NC*	Female	22.78	25	110
Total	6.15	13	212 #+				
Lung and Bronchu				All Sites / Types			
Male	60.08	62	103	Male	378.61	457	121 ^+
Female	49.76	52	105	Female	369.60	377	102
Total	109.83	114	104	Total	748.21	834	111 ~+

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \leq$ 0.05 level

^{* =} SIR and statistical significance not calculated when **Obs** < 5

[~] indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

Savoy
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	0.44	2	NC*	Male	0.31	0	NC*
Female	0.13	0	NC*	Female	0.21	0	NC*
Total	0.57	2	NC*	Total	0.51	0	NC*
Brain and Other Cent	ral Nervous S	<u>System</u>		Multiple Myeloma			
Male	0.14	0	NC*	Male	0.09	0	NC*
Female	0.10	0	NC*	Female	0.07	1	NC*
Total	0.24	0	NC*	Total	0.15	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>phoma</u>		
Male	0.02	0	NC*	Male	0.37	0	NC*
Female	2.50	3	NC*	Female	0.28	0	NC*
Total	2.52	3	NC*	Total	0.64	0	NC*
Cervix Uteri				Oral Cavity and Phary			
				Male	0.29	0	NC*
Female	0.15	0	NC*	Female	0.12	0	NC*
				Total	0.41	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	1.09	2	NC*				
Female	0.84	0	NC*	Female	0.29	0	NC*
Total	1.92	2	NC*	_			
<u>Esophagus</u>				<u>Pancreas</u>		_	
Male	0.16	0	NC*	Male	0.19	0	NC*
Female	0.04	0	NC*	Female	0.15	0	NC*
Total	0.20		NC*	Total	0.34	0	NC*
Hodgkin's Disease (H			Not	<u>Prostate</u>	0.74	•	1104
Male	0.07	0	NC*	Male	2.74	2	NC*
Female	0.05	0	NC*				
Total	0.12	0	NC*	Otamaah			
Kidney and Renal Pel		0	NO*	<u>Stomach</u>	0.40	0	NOt
Male	0.27	0	NC*	Male	0.19	0	NC*
Female	0.14	0	NC*	Female	0.09	0	NC*
Total	0.41	0	NC*	Total	0.27	0	NC*
<u>Larynx</u> Male	0.15	٥	NC*	<u>Testis</u> Male	0.11	0	NC*
Female	0.15	0 0	NC*	Male	0.11	U	NC
Total	0.03	0	NC*				
Leukemia	0.19	U	NC	<u>Thyroid</u>			
Male	0.21	0	NC*	<u>rriyroid</u> Male	0.06	0	NC*
Female	0.21	1	NC*	Female	0.00	0	NC*
Total	0.14	1	NC*	Total	0.13	0	NC*
Liver and Intrahepation		į	NO	Uteri, Corpus and Ute		U	NC
Male	0.10	1	NC*	oten, corpus and ote	1143, 110 <u>0</u>		
Female	0.10	0	NC*	Female	0.49	1	NC*
Total	0.14	1	NC*	i omalo	3.10	'	110
Lung and Bronchus	V. 17	1	110	All Sites / Types			
Male	1.39	0	NC*	Male	9.00	7	78
Female	0.99	1	NC*	Female	7.49	7	93
i omalo	0.00		110	i omaio	7.10	,	50

Total 2.38 1 NC* Total 16.49 14 85

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Scituate
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	•		,		,		
	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	11.89	9	76	Male	7.82	13	166
Female	4.60	6	130	Female	5.98	9	150
Total	16.48	15	91	Total	13.80	22	159
Brain and Other Ce	entral Nervous S	<u>iystem</u>		Multiple Myeloma			
Male	3.47	3	NC*	Male	2.35	0	NC*
Female	2.85	4	NC*	Female	2.10	1	NC*
Total	6.32	7	111	Total	4.45	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	nphoma		
Male	0.57	1	NC*	Male	9.39	9	96
Female	74.21	86	116	Female	8.71	10	115
Total	74.78	87	116	Total	18.10	19	105
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	7.55	9	119
Female	3.95	2	NC*	Female	3.68	8	217
				Total	11.23	17	151
Colon / Rectum				<u>Ovary</u>			
Male	29.65	25	84				
Female	28.74	22	77	Female	8.56	8	93
Total	58.39	47	80				
Esophagus				<u>Pancreas</u>			
Male	4.38	1	NC*	Male	5.05	6	119
Female	1.40	0	NC*	Female	5.35	8	150
Total	5.78	1	NC*	Total	10.39	14	135
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	1.59	0	NC*	Male	76.58	82	107
Female	1.27	0	NC*				
Total	2.87	0	NC*				
Kidney and Renal I	<u>Pelvis</u>			Stomach			
Male	7.08	10	141	Male	5.00	1	NC*
Female	4.50	2	NC*	Female	3.09	2	NC*
Total	11.59	12	104	Total	8.09	3	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	4.13	4	NC*	Male	2.23	2	NC*
Female	1.06	2	NC*				
Total	5.19	6	116				

^{* =} SIR and statistical significance not calculated when Obs < 5

<u>Leukemia</u>				<u>Thyroid</u>			
Male	5.49	4	NC*	Male	1.50	2	NC*
Female	4.40	7	159	Female	3.92	4	NC*
Total	9.88	11	111	Total	5.42	6	111
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	2.76	3	NC*				
Female	1.17	1	NC*	Female	14.58	17	117
Total	3.93	4	NC*				
Lung and Bronchu	<u>s</u>			All Sites / Types			
Male	38.47	41	107	Male	242.74	242	100
Female	31.28	30	96	Female	232.04	240	103
Total	69.75	71	102	Total	474.77	482	102

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Seekonk
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	10.00	11	110	Male	6.75	6	89
Female	3.49	0	NC*	Female	4.89	5	102
Total	13.49	11	82	Total	11.64	11	94
Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	3.00	5	167	Male	1.99	1	NC*
Female	2.31	2	NC*	Female	1.64	2	NC*
Total	5.31	7	132	Total	3.62	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn			
Male	0.48	1	NC*	Male	8.06	3	NC*
Female	60.26	56	93	Female	6.83	5	73
Total	60.75	57	94	Total	14.90	8	54
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	6.52	9	138
Female	3.32	1	NC*	Female	2.93	0	NC*
				Total	9.44	9	95
Colon / Rectum				<u>Ovary</u>			
Male	25.00	18	72				
Female	21.79	25	115	Female	6.98	8	115
Total	46.80	43	92				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	3.74	3	NC*	Male	4.28	2	NC*
Female	1.06	2	NC*	Female	4.06	1	NC*
Total	4.80	5	104	Total	8.34	3	NC*
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Male	1.41	0	NC*	Male	64.88	46	71 #-
Female	1.07	0	NC*				
Total	2.48	0	NC*				
Kidney and Renal Po	<u>elvis</u>			Stomach			
Male	6.06	4	NC*	Male	4.24	8	189
Female	3.56	1	NC*	Female	2.33	0	NC*
Total	9.63	5	52	Total	6.58	8	122
<u>Larynx</u>				<u>Testis</u>			
Male	3.54	1	NC*	Male	2.03	3	NC*
Female	0.85	0	NC*				
Total	4.39	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	4.67	6	128	Male	1.32	1	NC*
Female	3.46	3	NC*	Female	3.34	3	NC*
Total	8.13	9	111	Total	4.66	4	NC*
Liver and Intrahepat	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	2.37	0	NC*				
Female	0.90	1	NC*	Female	11.83	8	68
Total	3.26	1	NC*				
Lung and Bronchus	1			All Sites / Types			
Male	32.52	11	34 ^-	Male	206.32	150	73 ∧-
Female	24.60	20	81	Female	184.34	152	82 #-
Total	57.11	31	54 ^-	Total	390.66	302	77 ^-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- ^ indicates statistical significance at the p ≤ 0.001 level, as well as at the p ≤ 0.05 and p ≤ 0.01 levels

SharonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	10.88	12	110	Male	7.63	7	92
Female	3.77	2	NC*	Female	5.49	13	237 ~+
Total	14.65	14	96	Total	13.12	20	152
Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	3.45	2	NC*	Male	2.22	5	225
Female	2.60	7	270 #+	Female	1.79	2	NC*
Total	6.04	9	149	Total	4.01	7	174
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Male	0.54	0	NC*	Male	9.04	18	199 #+
Female	68.24	79	116	Female	7.45	10	134
Total	68.77	79	115	Total	16.49	28	170 #+
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	7.55	5	66

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	3.72	3	NC*	Female	3.28	1	NC*
				Total	10.83	6	55
Colon / Rectum				<u>Ovary</u>			
Male	27.25	24	88				
Female	23.45	16	68	Female	7.87	10	127
Total	50.71	40	79				
Esophagus				<u>Pancreas</u>			
Male	4.23	2	NC*	Male	4.74	7	148
Female	1.14	2	NC*	Female	4.38	1	NC*
Total	5.38	4	NC*	Total	9.12	8	88
Hodgkin's Disease	(Hodgkin Lympl	homa <u>)</u>		Prostate			
Male	1.58	1	NC*	Male	71.72	65	91
Female	1.17	1	NC*				
Total	2.74	2	NC*				
Kidney and Renal	<u>Pelvis</u>			Stomach			
Male	6.91	5	72	Male	4.68	4	NC*
Female	3.96	4	NC*	Female	2.53	8	317 ~+
Total	10.87	9	83	Total	7.21	12	166
<u>Larynx</u>				<u>Testis</u>			
Male	4.04	3	NC*	Male	2.16	0	NC*
Female	0.96	0	NC*				
Total	5.00	3	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	5.27	6	114	Male	1.51	6	397 #+
Female	3.92	2	NC*	Female	3.73	12	322 ~+
Total	9.18	8	87	Total	5.24	18	343 ^+
Liver and Intrahep	atic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	2.68	1	NC*				
Female	0.98	1	NC*	Female	13.43	11	82
Total	3.66	2	NC*				
Lung and Bronchu	<u>IS</u>			All Sites / Types			
Male	35.79	24	67 #-	Male	228.70	208	91
Female	26.89	17	63	Female	204.85	214	104
Total	62.68	41	65 ~-	Total	433.56	422	97

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Sheffield Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	2.53	1	NC*	Male	1.64	1	NC*
Female	0.86	0	NC*	Female	1.14	0	NC*

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Total	3.39	1	NC*	Total	2.77	1	NC*
Brain and Other Co	entral Nervous Sy	<u>ystem</u>		Multiple Myeloma			
Male	0.71	1	NC*	Male	0.49	1	NC*
Female	0.54	0	NC*	Female	0.39	0	NC*
Total	1.26	1	NC*	Total	0.88	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	mphoma		
Male	0.12	0	NC*	Male	1.98	2	NC*
Female	13.89	7	50	Female	1.64	0	NC*
Total	14.01	7	50	Total	3.61	2	NC*
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	1.56	4	NC*
Female	0.76	0	NC*	Female	0.69	0	NC*
				Total	2.25	4	NC*
Colon / Rectum				<u>Ovary</u>			
Male	6.28	6	96				
Female	5.37	7	130	Female	1.61	1	NC*
Total	11.64	13	112				
Esophagus				<u>Pancreas</u>			
Male	0.91	0	NC*	Male	1.06	1	NC*
Female	0.26	0	NC*	Female	1.00	0	NC*
Total	1.17	0	NC*	Total	2.06	1	NC*
Hodgkin's Disease (Hodgkin Lymphoma)				<u>Prostate</u>			
Male	0.33	0	NC*	Male	15.76	13	82
Female	0.25	0	NC*				
Total	0.58	0	NC*				
Kidney and Renal	<u>Pelvis</u>			<u>Stomach</u>			
Male	1.47	2	NC*	Male	1.07	0	NC*
Female	0.84	1	NC*	Female	0.58	1	NC*
Total	2.31	3	NC*	Total	1.64	1	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.85	1	NC*	Male	0.47	1	NC*
Female	0.20	0	NC*				
Total	1.05	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	1.15	1	NC*	Male	0.31	1	NC*
Female	0.83	0	NC*	Female	0.76	0	NC*
Total	1.98	1	NC*	Total	1.07	1	NC*
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	0.57	0	NC*				
Female	0.22	0	NC*	Female	2.71	2	NC*
Total	0.79	0	NC*				
Lung and Bronchu	<u>IS</u>			All Sites / Types			
Male	7.99	8	100	Male	50.62	46	91
Female	5.83	3	NC*	Female	43.47	26	60 ~-
Total	13.82	11	80	Total	94.08	72	77 #-

Obs = observed case count

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

ShelburneExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	1.36	3	NC*	Male	0.96	1	NC*
Female	0.72	1	NC*	Female	0.85	2	NC*
Total	2.08	4	NC*	Total	1.81	3	NC*
Brain and Other Cen	<u>tral Nervous S</u>	<u>system</u>		Multiple Myeloma			
Male	0.43	1	NC*	Male	0.28	0	NC*
Female	0.39	0	NC*	Female	0.31	1	NC*
Total	0.82	1	NC*	Total	0.58	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>iphoma</u>		
Male	0.07	0	NC*	Male	1.14	1	NC*
Female	10.40	7	67	Female	1.27	1	NC*
Total	10.46	7	67	Total	2.41	2	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	0.93	1	NC*
Female	0.54	0	NC*	Female	0.53	0	NC*
				Total	1.47	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	3.41	2	NC*				
Female	4.52	4	NC*	Female	1.19	0	NC*
Total	7.92	6	76				
Esophagus				<u>Pancreas</u>			
Male	0.52	0	NC*	Male	0.59	1	NC*
Female	0.22	0	NC*	Female	0.82	0	NC*
Total	0.74	0	NC*	Total	1.41	1	NC*
Hodgkin's Disease (I	lodgkin Lymp	homa)		<u>Prostate</u>			
Male	0.21	0	NC*	Male	8.84	9	102
Female	0.18	0	NC*				
Total	0.38	0	NC*				
Kidney and Renal Pe	lvis			Stomach			
Male	0.86	0	NC*	Male	0.58	0	NC*
Female	0.64	1	NC*	Female	0.50	1	NC*
Total	1.50	1	NC*	Total	1.08	1	NC*
<u>Larynx</u>				<u>Testis</u>			
 Male	0.50	1	NC*	 Male	0.30	0	NC*
Female	0.14	0	NC*				
Total	0.64	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.66	1	NC*	Male	0.19	0	NC*
Female	0.66	0	NC*	Female	0.53	0	NC*
Total	1.32	1	NC*	Total	0.73	0	NC*
Liver and Intrahepati				Uteri, Corpus and Ute			
Male	0.33	0	NC*				
Female	0.18	0	NC*	Female	2.00	4	NC*
Total	0.51	0	NC*				-
Lung and Bronchus	•	-		All Sites / Types			

Male	4.45	2	NC*	Male	28.48	26	91
Female	4.32	8	185	Female	33.50	34	101
Total	8.77	10	114	Total	61.98	60	97

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Sherborn
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	2.87	2	NC*	Male	2.06	2	NC*
Female	0.94	2	NC*	Female	1.46	2	NC*
Total	3.81	4	NC*	Total	3.52	4	NC*
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	0.92	1	NC*	Male	0.60	2	NC*
Female	0.68	2	NC*	Female	0.46	0	NC*
Total	1.60	3	NC*	Total	1.06	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	nphoma		
Male	0.14	0	NC*	Male	2.41	2	NC*
Female	18.39	22	120	Female	1.92	0	NC*
Total	18.54	22	119	Total	4.33	2	NC*
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	2.07	1	NC*
Female	1.01	0	NC*	Female	0.86	0	NC*
				Total	2.93	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	7.23	12	166				
Female	5.82	6	103	Female	2.12	2	NC*
Total	13.05	18	138				
Esophagus Page 1				<u>Pancreas</u>			
Male	1.15	1	NC*	Male	1.27	2	NC*
Female	0.28	0	NC*	Female	1.09	1	NC*
Total	1.43	1	NC*	Total	2.36	3	NC*
Hodgkin's Disease	(Hodgkin Lymp	homa)		<u>Prostate</u>			
Male	0.41	0	NC*	Male	19.43	21	108
Female	0.30	0	NC*				
Total	0.71	0	NC*				
Kidney and Renal P	<u>Pelvis</u>			<u>Stomach</u>			
Male	1.88	2	NC*	Male	1.24	2	NC*
Female	1.04	1	NC*	Female	0.62	1	NC*
Total	2.92	3	NC*	Total	1.87	3	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.11	2	NC*	Male	0.55	2	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	0.26	0	NC*				
Total	1.37	2	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	1.39	3	NC*	Male	0.41	1	NC*
Female	1.00	1	NC*	Female	1.01	2	NC*
Total	2.39	4	NC*	Total	1.42	3	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	0.73	0	NC*				
Female	0.25	1	NC*	Female	3.64	4	NC*
Total	0.98	1	NC*				
Lung and Bronchus	<u>3</u>			All Sites / Types			
Male	9.63	2	NC*	Male	61.42	62	101
Female	7.07	10	141	Female	53.81	58	108
Total	16.70	12	72	Total	115.23	120	104

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- ^ indicates statistical significance at the p ≤ 0.001 level, as well as at the p ≤ 0.05 and p ≤ 0.01 levels

ShirleyExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		Exp	Obs	SIR
Bladder, Urinary		<u> </u>		Melanoma of Skin			
Male	3.49	8	229	Male	2.90	2	NC*
Female	1.14	2	NC*	Female	1.99	1	NC*
Total	4.63	10	216 #+	Total	4.89	3	NC*
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	1.39	0	NC*	Male	0.73	0	NC*
Female	0.95	1	NC*	Female	0.55	0	NC*
Total	2.34	1	NC*	Total	1.29	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>iphoma</u>		
Male	0.18	0	NC*	Male	3.42	3	NC*
Female	22.49	17	76	Female	2.48	6	242
Total	22.67	17	75	Total	5.90	9	153
Cervix Uteri				Oral Cavity and Pharynx			
				Male	2.71	0	NC*
Female	1.49	0	NC*	Female	1.05	1	NC*
				Total	3.76	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	8.92	12	135				
Female	7.10	8	113	Female	2.69	3	NC*
Total	16.01	20	125				
Esophagus				<u>Pancreas</u>			
Male	1.43	1	NC*	Male	1.57	0	NC*
Female	0.34	1	NC*	Female	1.33	0	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Total	1.77	2	NC*	Total	2.91	0	NC*
Hodgkin's Disease	(Hodgkin Lymph	<u>ioma)</u>		<u>Prostate</u>			
Male	0.82	0	NC*	Male	23.67	24	101
Female	0.54	1	NC*				
Total	1.36	1	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	2.43	4	NC*	Male	1.54	4	NC*
Female	1.28	0	NC*	Female	0.77	1	NC*
Total	3.71	4	NC*	Total	2.31	5	216
<u>Larynx</u>				<u>Testis</u>			
Male	1.39	2	NC*	Male	1.42	1	NC*
Female	0.30	1	NC*				
Total	1.70	3	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	1.91	1	NC*	Male	0.70	1	NC*
Female	1.30	1	NC*	Female	1.59	2	NC*
Total	3.20	2	NC*	Total	2.29	3	NC*
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and U	<u>Iterus, NOS</u>		
Male	0.94	1	NC*				
Female	0.30	0	NC*	Female	4.28	9	210
Total	1.25	1	NC*				
Lung and Bronchu	<u>s</u>			All Sites / Types			
Male	11.88	11	93	Male	78.79	78	99
Female	8.56	8	93	Female	66.98	72	107
Total	20.44	19	93	Total	145.76	150	103

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

ShrewsburyExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	17.83	21	118	Male	12.34	14	113
Female	6.72	6	89	Female	9.34	9	96
Total	24.55	27	110	Total	21.68	23	106
Brain and Other Ce	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	5.60	5	89	Male	3.55	2	NC*
Female	4.45	7	157	Female	3.10	6	193
Total	10.06	12	119	Total	6.66	8	120
<u>Breast</u>				Non-Hodgkin('s) Lyr	nphoma		
Male	0.86	1	NC*	Male	14.79	21	142
Female	112.56	107	95	Female	13.12	11	84
Total	113.42	108	95	Total	27.92	32	115

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Cervix Uteri							
				Male	11.66	10	86
Female	6.40	2	NC*	Female	5.51	4	NC*
				Total	17.17	14	82
Colon / Rectum				<u>Ovary</u>			
Male	44.59	43	96				
Female	42.12	44	104	Female	13.13	15	114
Total	86.71	87	100				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	6.61	3	NC*	Male	7.59	12	158
Female	2.05	3	NC*	Female	7.81	11	141
Total	8.66	6	69	Total	15.40	23	149
Hodgkin's Disease	(Hodgkin Lympl	<u>homa)</u>		Prostate			
Male	2.82	4	NC*	Male	114.11	115	101
Female	2.15	3	NC*				
Total	4.97	7	141				
Kidney and Renal	<u>Pelvis</u>			Stomach			
Male	10.92	15	137	Male	7.55	6	80
Female	6.73	9	134	Female	4.52	2	NC*
Total	17.65	24	136	Total	12.07	8	66
<u>Larynx</u>				<u>Testis</u>			
Male	6.28	4	NC*	Male	4.31	5	116
Female	1.58	0	NC*				
Total	7.85	4	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	8.60	9	105	Male	2.51	3	NC*
Female	6.64	2	NC*	Female	6.51	10	154
Total	15.24	11	72	Total	9.03	13	144
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and L	<u> Iterus, NOS</u>		
Male	4.24	2	NC*				
Female	1.72	1	NC*	Female	21.89	24	110
Total	5.96	3	NC*				
Lung and Bronchu	<u>IS</u>			All Sites / Types			
Male	57.82	50	86	Male	369.16	367	99
Female	46.42	45	97	Female	349.21	348	100
Total	104.23	95	91	Total	718.37	715	100

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the p ≤ 0.001 level, as well as at the p ≤ 0.05 and p ≤ 0.01 levels

Shutesbury

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

<u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Bladder, Urinary</u> <u>Melanoma of Skin</u>

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Male	0.95	0	NC*	Male	0.77	2	NC*
Female	0.31	0	NC*	Female	0.60	0	NC*
Total	1.26	0	NC*	Total	1.36	2	NC*
Brain and Other Cen	tral Nervous Sy	<u>rstem</u>		Multiple Myeloma			
Male	0.36	0	NC*	Male	0.20	0	NC*
Female	0.27	1	NC*	Female	0.16	0	NC*
Total	0.63	1	NC*	Total	0.36	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	<u>nphoma</u>		
Male	0.05	0	NC*	Male	0.90	0	NC*
Female	6.84	6	88	Female	0.70	0	NC*
Total	6.89	6	87	Total	1.59	0	NC*
Cervix Uteri				Oral Cavity and Pha			
				Male	0.76	0	NC*
Female	0.45	0	NC*	Female	0.31	0	NC*
				Total	1.08	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	2.40	3	NC*				
Female	1.95	1	NC*	Female	0.81	0	NC*
Total	4.35	4	NC*				-
Esophagus				Pancreas			
Male	0.40	0	NC*	Male	0.43	0	NC*
Female	0.09	0	NC*	Female	0.36	0	NC*
Total	0.50	0	NC*	Total	0.79	0	NC*
Hodgkin's Disease (-		Prostate	S C	·	
Male	0.18	0	NC*	Male	6.49	6	93
Female	0.15	0	NC*	maio	0.10	v	
Total	0.34	0	NC*				
Kidney and Renal Pe		·		Stomach			
Male	0.67	0	NC*	Male	0.43	2	NC*
Female	0.37	0	NC*	Female	0.21	1	NC*
Total	1.04	0	NC*	Total	0.64	3	NC*
<u>Larynx</u>		v		<u>Testis</u>	0.01	· ·	110
Male	0.39	0	NC*	Male	0.28	0	NC*
Female	0.09	0	NC*	Wale	0.20	v	110
Total	0.48	0	NC*				
<u>Leukemia</u>	0.10	v	110	<u>Thyroid</u>			
Male	0.51	0	NC*	Male	0.17	0	NC*
Female	0.37	0	NC*	Female	0.48	0	NC*
Total	0.88	0	NC*	Total	0.45	0	NC*
Liver and Intrahepat		v	110	Uteri, Corpus and Ut		v	110
Male	0.26	0	NC*	oten, oorpas ana or	<u>icrus, 1100</u>		
Female	0.20	0	NC*	Female	1.30	1	NC*
Total	0.34	0	NC*	remaie	1.00	'	110
Lung and Bronchus		U	140	All Sites / Types			
Male	3.22	0	NC*	Male	21.22	13	61
Female	2.40	1	NC*	Female	19.57	11	56
Total	5.61	1	NC*	Total	40.79	24	
i Uldi	5.01	ı	NO	ı Ulaı	40.73	24	59 ~-

Obs = observed case count

 $^{^{\}star}$ = SIR and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Somerset
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	15.93	15	94	Male	9.95	5	50
Female	6.28	5	80	Female	7.48	6	80
Total	22.21	20	90	Total	17.43	11	63
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	4.26	6	141	Male	3.08	3	NC*
Female	3.52	5	142	Female	2.81	3	NC*
Total	7.78	11	141	Total	5.89	6	102
<u>Breast</u>				Non-Hodgkin('s) Lyn	<u>nphoma</u>		
Male	0.74	0	NC*	Male	12.01	15	125
Female	94.54	93	98	Female	11.48	11	96
Total	95.28	93	98	Total	23.49	26	111
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	9.46	6	63
Female	4.75	5	105	Female	4.78	4	NC*
				Total	14.24	10	70
Colon / Rectum				<u>Ovary</u>			
Male	39.45	30	76				
Female	39.36	35	89	Female	10.82	11	102
Total	78.81	65	82				
Esophagus				<u>Pancreas</u>			
Male	5.62	9	160	Male	6.61	9	136
Female	1.93	2	NC*	Female	7.29	6	82
Total	7.55	11	146	Total	13.91	15	108
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		Prostate			
Male	1.90	2	NC*	Male	99.31	116	117
Female	1.48	2	NC*				
Total	3.38	4	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	9.04	7	77	Male	6.61	8	121
Female	5.88	7	119	Female	4.22	5	119
Total	14.92	14	94	Total	10.83	13	120
<u>Larynx</u>				<u>Testis</u>			
Male	5.24	6	115	Male	2.64	3	NC*
Female	1.37	0	NC*				
Total	6.61	6	91				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	7.02	9	128	Male	1.81	0	NC*
Female	5.61	6	107	Female	4.60	4	NC*
Total	12.63	15	119	Total	6.41	4	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and Ut	terus, NOS		
Male	3.53	1	NC*				
Female	1.57	1	NC*	Female	18.68	19	102

Total	5.10	2	NC*				
Lung and Bronchus	<u>.</u>			All Sites / Types			
Male	50.40	52	103	Male	315.29	319	101
Female	41.45	26	63 #-	Female	302.05	272	90
Total	91.85	78	85	Total	617.34	591	96

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

SomervilleExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Ехр	<u>Obs</u>	SIR		Ехр	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	38.60	37	96	Male	28.28	13	46 ~-
Female	18.19	19	104	Female	25.70	18	70
Total	56.78	56	99	Total	53.98	31	57 ∧-
Brain and Other Co	entral Nervous S	<u>System</u>		Multiple Myeloma			
Male	13.02	9	69	Male	7.47	8	107
Female	11.79	10	85	Female	7.96	9	113
Total	24.81	19	77	Total	15.43	17	110
<u>Breast</u>				Non-Hodgkin('s) Lyı	mphoma		
Male	1.82	0	NC*	Male	34.35	19	55 ~-
Female	284.54	251	88 #-	Female	35.24	26	74
Total	286.35	251	88 #-	Total	69.58	45	65 ~-
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	24.51	29	118
Female	18.55	19	102	Female	14.11	10	71
				Total	38.62	39	101
Colon / Rectum				<u>Ovary</u>			
Male	96.21	119	124 #+				
Female	114.85	145	126 ~+	Female	33.92	22	65 #-
Total	211.06	264	125 ^+				
Esophagus				<u>Pancreas</u>			
Male	13.56	18	133	Male	16.14	15	93
Female	5.56	4	NC*	Female	20.92	17	81
Total	19.12	22	115	Total	37.07	32	86
Hodgkin's Disease				<u>Prostate</u>			
Male	8.17	8	98	Male	229.58	196	85 #-
Female	6.83	6	88				
Total	15.00	14	93				
Kidney and Renal				<u>Stomach</u>			
Male	23.14	22	95	Male	16.44	19	116
Female	17.12	16	93	Female	12.67	21	166 #+
Total	40.26	38	94	Total	29.10	40	137

^{* =} SIR and statistical significance not calculated when **Obs** < 5

<u>Larynx</u>				<u>Testis</u>			
Male	12.72	14	110	Male	14.62	21	144
Female	3.75	8	214				
Total	16.47	22	134				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	19.34	16	83	Male	6.49	5	77
Female	17.49	23	132	Female	19.66	14	71
Total	36.83	39	106	Total	26.15	19	73
	ahepatic Bile Ducts						
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Liver and Intrahepa Male	8.92	7	78	Uteri, Corpus and U	<u>Iterus, NOS</u>		
-		7 3	78 NC*	Uteri, Corpus and U	52.81	42	80
Male	8.92			-		42	80
Male Female	8.92 4.54 13.46	3	NC*	-		42	80
Male Female Total	8.92 4.54 13.46	3	NC*	Female		42 790	80
Male Female Total Lung and Bronchus	8.92 4.54 13.46 <u>s</u>	3 10	NC* 74	Female All Sites / Types	52.81		

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- ^ indicates statistical significance at the p ≤ 0.001 level, as well as at the p ≤ 0.05 and p ≤ 0.01 levels

South HadleyExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	12.16	15	123	Male	7.72	13	168
Female	5.11	9	176	Female	6.65	8	120
Total	17.27	24	139	Total	14.37	21	146
Brain and Other Cer	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	3.36	4	NC*	Male	2.34	3	NC*
Female	3.20	1	NC*	Female	2.26	0	NC*
Total	6.56	5	76	Total	4.61	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	nphoma		
Male	0.56	0	NC*	Male	9.36	11	117
Female	78.26	76	97	Female	9.67	11	114
Total	78.82	76	96	Total	19.03	22	116
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	7.21	11	153
Female	4.51	7	155	Female	3.93	4	NC*
				Total	11.14	15	135
Colon / Rectum				<u>Ovary</u>			
Male	30.10	26	86				
Female	32.18	27	84	Female	9.18	11	120
Total	62.28	53	85				
<u>Esophagus</u>				<u>Pancreas</u>			

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Male	4.25	9	212	Male	5.03	11	219 #+
Female	1.56	1	NC*	Female	5.90	7	119
Total	5.82	10	172	Total	10.93	18	165
Hodgkin's Disease	(Hodgkin Lymph	noma <u>)</u>		<u>Prostate</u>			
Male	1.60	1	NC*	Male	74.77	51	68 ~-
Female	1.60	2	NC*				
Total	3.20	3	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	6.92	8	116	Male	5.05	3	NC*
Female	4.82	3	NC*	Female	3.49	5	143
Total	11.73	11	94	Total	8.54	8	94
<u>Larynx</u>				<u>Testis</u>			
Male	3.96	6	151	Male	2.35	4	NC*
Female	1.08	0	NC*				
Total	5.04	6	119				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	5.48	3	NC*	Male	1.45	3	NC*
Female	4.90	3	NC*	Female	4.63	3	NC*
Total	10.38	6	58	Total	6.08	6	99
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	2.69	1	NC*				
Female	1.28	1	NC*	Female	15.00	11	73
Total	3.97	2	NC*				
Lung and Bronchu	<u>s</u>			All Sites / Types			
Male	38.23	31	81	Male	240.69	230	96
Female	33.21	37	111	Female	251.04	244	97
Total	71.43	68	95	Total	491.74	474	96

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Southampton
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	3.27	3	NC*	Male	2.31	3	NC*
Female	1.17	0	NC*	Female	1.71	2	NC*
Total	4.45	3	NC*	Total	4.03	5	124
Brain and Other Cen	tral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	1.05	2	NC*	Male	0.67	0	NC*
Female	0.82	0	NC*	Female	0.56	0	NC*
Total	1.87	2	NC*	Total	1.23	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>phoma</u>		
Male	0.16	0	NC*	Male	2.74	1	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	21.06	12	57 #-	Female	2.35	2	NC*
Total	21.22	12	57 #-	Total	5.10	3	NC*
Cervix Uteri				Oral Cavity and Pha	<u>arynx</u>		
				Male	2.25	0	NC*
Female	1.18	0	NC*	Female	1.01	1	NC*
				Total	3.26	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	8.20	8	98				
Female	7.33	7	96	Female	2.45	3	NC*
Total	15.53	15	97				
Esophagus				<u>Pancreas</u>			
Male	1.26	1	NC*	Male	1.42	0	NC*
Female	0.36	0	NC*	Female	1.37	0	NC*
Total	1.61	1	NC*	Total	2.78	0	NC*
Hodgkin's Disease	(Hodgkin Lympl	noma)		<u>Prostate</u>			
Male	0.50	1	NC*	Male	21.37	16	75
Female	0.38	0	NC*				
Total	0.88	1	NC*				
Kidney and Renal P	<u>'elvis</u>			Stomach			
Male	2.08	0	NC*	Male	1.40	1	NC*
Female	1.23	2	NC*	Female	0.78	1	NC*
Total	3.31	2	NC*	Total	2.18	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.20	0	NC*	Male	0.72	2	NC*
Female	0.30	1	NC*				
Total	1.50	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	1.59	0	NC*	Male	0.47	0	NC*
Female	1.20	0	NC*	Female	1.19	2	NC*
Total	2.79	0	NC*	Total	1.66	2	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	0.80	0	NC*				
Female	0.30	0	NC*	Female	4.14	3	NC*
Total	1.11	0	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	10.75	6	56	Male	68.71	52	76 #-
Female	8.53	7	82	Female	63.79	48	75 #-
Total	19.28	13	67	Total	132.50	100	75 ~ -

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

^{* =} SIR and statistical significance not calculated when **Obs** < 5

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	4.17	2	NC*	Male	3.16	4	NC*
Female	1.49	0	NC*	Female	2.39	2	NC*
Total	5.66	2	NC*	Total	5.55	6	108
Brain and Other Cer	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	1.48	4	NC*	Male	0.87	0	NC*
Female	1.12	0	NC*	Female	0.73	0	NC*
Total	2.60	4	NC*	Total	1.60	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	<u>mphoma</u>		
Male	0.21	0	NC*	Male	3.73	2	NC*
Female	28.90	33	114	Female	3.09	6	194
Total	29.11	33	113	Total	6.82	8	117
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	3.08	1	NC*
Female	1.69	0	NC*	Female	1.36	0	NC*
				Total	4.44	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	10.53	3	NC*				
Female	9.31	8	86	Female	3.37	1	NC*
Total	19.83	11	55 #-				
Esophagus				<u>Pancreas</u>			
Male	1.68	1	NC*	Male	1.85	4	NC*
Female	0.45	1	NC*	Female	1.73	0	NC*
Total	2.13	2	NC*	Total	3.58	4	NC*
Hodgkin's Disease	(Hodgkin Lymp	homa)		Prostate			
Male	0.75	4	NC*	Male	27.98	21	75
Female	0.54	0	NC*				
Total	1.30	4	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	2.79	4	NC*	Male	1.82	2	NC*
Female	1.64	4	NC*	Female	1.00	2	NC*
Total	4.42	8	181	Total	2.82	4	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.62	0	NC*	Male	1.13	2	NC*
Female	0.40	0	NC*				
Total	2.02	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.15	1	NC*	Male	0.68	0	NC*
Female	1.62	1	NC*	Female	1.73	2	NC*
Total	3.77	2	NC*	Total	2.41	2	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and Ut	terus, NOS		
Male	1.08	2	NC*				
Female	0.39	1	NC*	Female	5.64	6	106
Total	1.47	3	NC*				
Lung and Bronchus	<u>i</u>			All Sites / Types			
Male	13.96	7	50	Male	90.69	77	85
Female	11.03	10	91	Female	85.34	84	98
Total	24.99	17	68	Total	176.02	161	91

Obs = observed case count

- * = **SIR** and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

SouthbridgeExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	11.63	18	155	Male	7.26	5	69
Female	5.45	4	NC*	Female	6.22	2	NC*
Total	17.09	22	129	Total	13.48	7	52
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	3.19	7	219	Male	2.17	3	NC*
Female	2.94	4	NC*	Female	2.29	0	NC*
Total	6.13	11	179	Total	4.46	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	<u>mphoma</u>		
Male	0.52	1	NC*	Male	8.98	7	78
Female	73.69	79	107	Female	9.60	10	104
Total	74.21	80	108	Total	18.58	17	91
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	6.50	3	NC*
Female	3.96	5	126	Female	3.85	6	156
				Total	10.36	9	87
Colon / Rectum				<u>Ovary</u>			
Male	28.42	31	109				
Female	34.43	29	84	Female	8.55	11	129
Total	62.85	60	95				
Esophagus				<u>Pancreas</u>			
Male	3.83	1	NC*	Male	4.70	6	128
Female	1.68	1	NC*	Female	6.22	7	112
Total	5.50	2	NC*	Total	10.92	13	119
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	1.66	2	NC*	Male	65.41	71	109
Female	1.41	2	NC*				
Total	3.07	4	NC*				
Kidney and Renal P				<u>Stomach</u>			
Male	6.30	9	143	Male	4.86	3	NC*
Female	4.68	1	NC*	Female	3.80	2	NC*
Total	10.98	10	91	Total	8.67	5	58
<u>Larynx</u>				<u>Testis</u>			
Male	3.47	10	288 ~+	Male	2.56	4	NC*
Female	1.00	1	NC*				
Total	4.48	11	246 #+				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	5.34	4	NC*	Male	1.39	1	NC*
Female	4.93	5	101	Female	3.98	1	NC*
Total	10.28	9	88	Total	5.37	2	NC*

Liver and Intrahepation	: Bile Ducts			Uteri, Corpus and Uterus, NOS				
Male	2.43	2	NC*					
Female	1.33	1	NC*	Female	14.01	9	64	
Total	3.76	3	NC*					
Lung and Bronchus				All Sites / Types				
Male	34.39	38	111	Male	220.69	248	112	
Female	32.03	14	44 ^-	Female	245.55	216	88	
Total	66.42	52	78	Total	466.23	464	100	

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** \leq 0.001 level, as well as at the **p** \leq 0.05 and **p** \leq 0.01 levels

SouthwickExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	4.60	5	109	Male	3.50	3	NC*
Female	1.59	3	NC*	Female	2.58	5	194
Total	6.19	8	129	Total	6.08	8	132
Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	1.64	1	NC*	Male	0.95	1	NC*
Female	1.23	1	NC*	Female	0.77	2	NC*
Total	2.87	2	NC*	Total	1.72	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	nphoma		
Male	0.23	0	NC*	Male	4.15	1	NC*
Female	30.51	29	95	Female	3.32	6	181
Total	30.74	29	94	Total	7.47	7	94
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	3.36	1	NC*
Female	1.86	2	NC*	Female	1.44	0	NC*
				Total	4.80	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	11.59	10	86				
Female	9.91	8	81	Female	3.59	3	NC*
Total	21.50	18	84				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	1.82	1	NC*	Male	2.03	1	NC*
Female	0.48	1	NC*	Female	1.85	4	NC*
Total	2.30	2	NC*	Total	3.88	5	129
Hodgkin's Disease	(Hodgkin Lymp	homa)		Prostate			
Male	0.86	1	NC*	Male	30.15	19	63 #-
Female	0.63	0	NC*				
Total	1.49	1	NC*				
Kidney and Renal P	<u>elvis</u>			<u>Stomach</u>			

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Male	3.05	3	NC*	Male	2.02	1	NC*
Female	1.74	1	NC*	Female	1.07	2	NC*
Total	4.79	4	NC*	Total	3.09	3	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.75	1	NC*	Male	1.34	3	NC*
Female	0.42	0	NC*				
Total	2.17	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.39	1	NC*	Male	0.77	0	NC*
Female	1.74	0	NC*	Female	1.93	3	NC*
Total	4.14	1	NC*	Total	2.70	3	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	1.18	1	NC*				
Female	0.42	1	NC*	Female	5.90	5	85
Total	1.60	2	NC*				
Lung and Bronchus	<u>3</u>			All Sites / Types			
Male	15.15	19	125	Male	99.19	82	83
Female	11.71	10	85	Female	90.79	93	102
Total	26.87	29	108	Total	189.98	175	92

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} < 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

SpencerExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	7.01	8	114	Male	4.89	1	NC*
Female	2.55	3	NC*	Female	3.72	2	NC*
Total	9.56	11	115	Total	8.61	3	NC*
Brain and Other Cer	<u>itral Nervous S</u>	<u>system</u>		Multiple Myeloma			
Male	2.24	1	NC*	Male	1.40	0	NC*
Female	1.78	1	NC*	Female	1.18	1	NC*
Total	4.02	2	NC*	Total	2.57	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Male	0.34	0	NC*	Male	5.88	7	119
Female	43.53	35	80	Female	5.08	11	217 #+
Total	43.87	35	80	Total	10.96	18	164
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	4.63	3	NC*
Female	2.62	6	229	Female	2.12	2	NC*
				Total	6.75	5	74
Colon / Rectum				<u>Ovary</u>			
Male	17.52	13	74				

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	16.03	16	100	Female	5.13	10	195
Total	33.55	29	86				
Esophagus Page 1				<u>Pancreas</u>			
Male	2.61	5	191	Male	3.00	5	167
Female	0.78	0	NC*	Female	2.95	1	NC*
Total	3.39	5	147	Total	5.95	6	101
Hodgkin's Disease	e (Hodgkin Lympl	noma)		<u>Prostate</u>			
Male	1.14	3	NC*	Male	44.76	33	74
Female	0.92	3	NC*				
Total	2.06	6	292 #+				
Kidney and Renal	<u>Pelvis</u>			Stomach			
Male	4.31	8	186	Male	2.99	0	NC*
Female	2.58	3	NC*	Female	1.73	3	NC*
Total	6.89	11	160	Total	4.72	3	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	2.48	0	NC*	Male	1.74	1	NC*
Female	0.60	0	NC*				
Total	3.07	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	3.42	2	NC*	Male	1.01	1	NC*
Female	2.60	3	NC*	Female	2.72	5	184
Total	6.02	5	83	Total	3.73	6	161
Liver and Intrahep	atic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	1.67	0	NC*				
Female	0.65	2	NC*	Female	8.35	7	84
Total	2.33	2	NC*				
Lung and Bronch	<u>us</u>			All Sites / Types			
Male	22.64	22	97	Male	145.41	121	83 #-
Female	17.57	28	159 #+	Female	134.74	149	111
Total	40.21	50	124	Total	280.14	270	96

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** \leq 0.001 level, as well as at the **p** \leq 0.05 and **p** \leq 0.01 levels

SpringfieldExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	83.06	76	91	Male	54.35	27	50 ^-
Female	37.01	33	89	Female	48.18	34	71 #-
Total	120.07	109	91	Total	102.53	61	59 ^-
Brain and Other Ce	entral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	25.19	22	87	Male	15.83	18	114
Female	23.45	18	77	Female	16.22	11	68

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Total	48.64	40	82	Total	32.05	29	90
<u>Breast</u>			-	Non-Hodgkin('s)			
Male	3.81	6	158	Male	67.02	78	116
Female	559.18	503	90 #-	Female	69.84	57	82
Total	562.99	509	90 #-	Total	136.86	135	99
Cervix Uteri				Oral Cavity and P	<u>Pharynx</u>		
				Male	49.02	63	129
Female	32.77	27	82	Female	28.24	23	81
				Total	77.26	86	111
Colon / Rectun	<u>1</u>			<u>Ovary</u>			
Male	205.10	205	100				
Female	233.13	221	95	Female	65.89	55	83
Total	438.23	426	97				
Esophagus				<u>Pancreas</u>			
Male	28.41	36	127	Male	34.12	39	114
Female	11.33	17	150	Female	42.64	35	82
Total	39.74	53	133	Total	76.76	74	96
Hodgkin's Dise	ase (Hodgkin Ly	<u>mphoma)</u>		<u>Prostate</u>			
Male	13.43	12	89	Male	492.39	471	96
Female	12.00	6	50				
Total	25.43	18	71				
Kidney and Re	<u>nal Pelvis</u>			Stomach			
Male	47.24	46	97	Male	34.72	36	104
Female	34.56	32	93	Female	25.46	26	102
Total	81.80	78	95	Total	60.17	62	103
<u>Larynx</u>				<u>Testis</u>			
Male		31	118	Male	20.94	8	38 ~-
Female	7.64	6	79				
Total	33.94	37	109				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	40.28	24	60 ~-	Male	10.92	5	46
Female		15	42 ^-	Female	33.94	22	65 #-
Total		39	51 ^-	Total	44.87	27	60 ~-
	hepatic Bile Duc			Uteri, Corpus and	d Uterus, NOS		
Male		29	159 #+				
Female		10	108	Female	106.43	106	100
Total		39	141 #+				
Lung and Bron				All Sites / Types			
Male		287	112	Male	1640.74	1642	100
Female		200	85 #-	Female	1805.06	1589	88 ^-
Total	491.55	487	99	Total	3445.79	3231	94 ^-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

SterlingExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	4.06	3	NC*	Male	3.09	1	NC*
Female	1.35	2	NC*	Female	2.19	2	NC*
Total	5.41	5	92	Total	5.28	3	NC*
Brain and Other Cer	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	1.44	1	NC*	Male	0.86	2	NC*
Female	1.03	1	NC*	Female	0.66	1	NC*
Total	2.46	2	NC*	Total	1.51	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	<u>nphoma</u>		
Male	0.21	0	NC*	Male	3.63	6	165
Female	26.35	28	106	Female	2.80	2	NC*
Total	26.56	28	105	Total	6.43	8	124
Cervix Uteri				Oral Cavity and Pha			
				Male	3.03	3	NC*
Female	1.56	1	NC*	Female	1.24	0	NC*
				Total	4.27	3	NC*
Colon / Rectum				<u>Ovary</u>			
Male	10.24	9	88				
Female	8.41	8	95	Female	3.07	2	NC*
Total	18.66	17	91				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	1.64	2	NC*	Male	1.80	1	NC*
Female	0.41	0	NC*	Female	1.56	1	NC*
Total	2.05	2	NC*	Total	3.37	2	NC*
Hodgkin's Disease (<u>Prostate</u>			
Male	0.71	0	NC*	Male	27.16	23	85
Female	0.51	2	NC*				
Total	1.22	2	NC*				
Kidney and Renal Po				<u>Stomach</u>			
Male	2.75	4	NC*	Male	1.78	0	NC*
Female	1.48	1	NC*	Female	0.91	1	NC*
Total .	4.23	5	118	Total	2.68	1	NC*
<u>Larynx</u>	4.50	•	NO*	<u>Testis</u>	4.00	4	NO*
Male	1.59	0	NC*	Male	1.06	4	NC*
Female	0.36	0	NC*				
Total	1.95	0	NC*	Thomasid			
<u>Leukemia</u>	0.40	2	NO*	<u>Thyroid</u>	0.00	0	NO*
Male	2.10	3	NC*	Male	0.66	0	NC*
Female	1.49	1	NC*	Female	1.60	2 2	NC*
Total	3.58	4	NC*	Total	2.26	2	NC*
Liver and Intrahepat Male	1.06	2	NC*	Uteri, Corpus and Ut	terus, NOS		
Female	0.35	0	NC*	Female	5.12	5	98
Total	1.41	2	NC*	Female	J. IZ	J	30
Lung and Bronchus		۷	NO	All Sites / Types			
Male	13.61	8	59	<u>All Sites / Types</u> Male	88.27	78	88
Female	9.94	14	141	Female	77.61	70 79	102
Total	23.54	22	93	Total	165.88	157	95
iolai	20.04	22	90	i Ulai	100.00	137	30

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

StockbridgeExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	•				•		
	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	2.05	2	NC*	Male	1.25	1	NC*
Female	0.81	1	NC*	Female	0.99	0	NC*
Total	2.86	3	NC*	Total	2.24	1	NC*
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	0.52	0	NC*	Male	0.39	0	NC*
Female	0.45	0	NC*	Female	0.36	0	NC*
Total	0.97	0	NC*	Total	0.75	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>iphoma</u>		
Male	0.09	2	NC*	Male	1.51	2	NC*
Female	12.43	9	72	Female	1.47	0	NC*
Total	12.53	11	88	Total	2.98	2	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	1.17	1	NC*
Female	0.64	0	NC*	Female	0.62	0	NC*
				Total	1.80	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	5.03	5	99				
Female	5.06	3	NC*	Female	1.42	2	NC*
Total	10.09	8	79				
Esophagus				<u>Pancreas</u>			
Male	0.70	1	NC*	Male	0.83	0	NC*
Female	0.25	1	NC*	Female	0.93	0	NC*
Total	0.95	2	NC*	Total	1.76	0	NC*
Hodgkin's Disease	(Hodgkin Lymp	homa)		<u>Prostate</u>			
Male	0.23	0	NC*	Male	12.23	6	49
Female	0.19	0	NC*				
Total	0.42	0	NC*				
Kidney and Renal P	<u>'elvis</u>			<u>Stomach</u>			
Male	1.14	1	NC*	Male	0.84	0	NC*
Female	0.75	0	NC*	Female	0.55	1	NC*
Total	1.90	1	NC*	Total	1.39	1	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.65	2	NC*	Male	0.31	0	NC*
Female	0.18	0	NC*				
Total	0.82	2	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Male	0.89	0	NC*	Male	0.22	0	NC*
Female	0.73	0	NC*	Female	0.62	0	NC*
Total	1.62	0	NC*	Total	0.84	0	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	0.44	0	NC*				
Female	0.20	0	NC*	Female	2.44	1	NC*
Total	0.64	0	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	6.34	3	NC*	Male	39.48	29	73
Female	5.24	3	NC*	Female	39.20	21	54 ~-
Total	11.57	6	52	Total	78.68	50	64 ^-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

StonehamExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary				Melanoma of Skin			
Male	15.85	10	63	Male	10.17	8	79
Female	6.88	5	73	Female	8.21	7	85
Total	22.73	15	66	Total	18.38	15	82
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	4.41	0	NC*	Male	3.04	2	NC*
Female	3.82	8	210	Female	2.97	2	NC*
Total	8.23	8	97	Total	6.02	4	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	<u>mphoma</u>		
Male	0.73	0	NC*	Male	12.35	9	73
Female	99.45	142	143 ^+	Female	12.39	11	89
Total	100.18	142	142 ^+	Total	24.74	20	81
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	9.43	9	95
Female	5.31	7	132	Female	5.08	4	NC*
				Total	14.51	13	90
Colon / Rectum				<u>Ovary</u>			
Male	39.18	48	122				
Female	43.21	52	120	Female	11.48	14	122
Total	82.39	100	121				
Esophagus				<u>Pancreas</u>			
Male	5.52	6	109	Male	6.56	10	152
Female	2.11	1	NC*	Female	7.91	9	114
Total	7.63	7	92	Total	14.47	19	131
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	2.18	7	321 #+	Male	95.99	101	105

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	1.77	0	NC*				
Total	3.96	7	177				
Kidney and Renal	<u>Pelvis</u>			Stomach			
Male	8.99	14	156	Male	6.63	9	136
Female	6.19	6	97	Female	4.73	4	NC*
Total	15.18	20	132	Total	11.36	13	114
<u>Larynx</u>				<u>Testis</u>			
Male	5.12	5	98	Male	3.30	4	NC*
Female	1.38	2	NC*				
Total	6.50	7	108				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	7.17	10	139	Male	1.95	3	NC*
Female	6.21	3	NC*	Female	5.28	8	151
Total	13.37	13	97	Total	7.24	11	152
Liver and Intrahepatic Bile Ducts			Uteri, Corpus and Uterus, NOS				
Male	3.49	1	NC*				
Female	1.70	6	354 #+	Female	19.18	20	104
Total	5.19	7	135				
Lung and Bronchi	<u>is</u>			All Sites / Types			
Male	49.25	60	122	Male	312.45	336	108
Female	42.78	43	101	Female	322.56	367	114 #+
Total	92.04	103	112	Total	635.01	703	111 ~+

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

StoughtonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR		
Bladder, Urinary				Melanoma of Skin					
Male	18.00	19	106	Male	12.46	5	40 #-		
Female	7.06	7	99	Female	9.84	14	142		
Total	25.05	26	104	Total	22.30	19	85		
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma					
Male	5.61	5	89	Male	3.57	2	NC*		
Female	4.62	4	NC*	Female	3.24	4	NC*		
Total	10.24	9	88	Total	6.81	6	88		
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma				
Male	0.86	0	NC*	Male	14.94	20	134		
Female	118.13	137	116	Female	13.74	16	116		
Total	118.99	137	115	Total	28.68	36	126		
Cervix Uteri				Oral Cavity and Pharynx					
				Male	11.71	11	94		
Female	6.78	3	NC*	Female	5.78	7	121		

^{* =} SIR and statistical significance not calculated when **Obs** < 5

				Total	17.49	18	103
Colon / Rectum				<u>Ovary</u>			
Male	44.94	53	118				
Female	44.14	43	97	Female	13.77	12	87
Total	89.08	96	108				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	6.63	3	NC*	Male	7.65	6	78
Female	2.15	2	NC*	Female	8.19	9	110
Total	8.78	5	57	Total	15.84	15	95
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		Prostate			
Male	2.87	7	244	Male	113.98	101	89
Female	2.26	1	NC*				
Total	5.14	8	156				
Kidney and Renal I	<u>Pelvis</u>			Stomach			
Male	10.96	10	91	Male	7.63	5	66
Female	7.04	13	185	Female	4.77	7	147
Total	18.00	23	128	Total	12.40	12	97
<u>Larynx</u>				<u>Testis</u>			
Male	6.28	1	NC*	Male	4.45	5	112
Female	1.65	2	NC*				
Total	7.93	3	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	8.63	11	127	Male	2.55	4	NC*
Female	6.92	2	NC*	Female	6.90	2	NC*
Total	15.54	13	84	Total	9.46	6	63
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and L	<u>Iterus, NOS</u>		
Male	4.25	3	NC*				
Female	1.80	1	NC*	Female	22.90	17	74
Total	6.05	4	NC*				
Lung and Bronchu	<u>s</u>			All Sites / Types			
Male	57.92	50	86	Male	370.73	354	95
Female	48.46	66	136 #+	Female	366.06	400	109
Total	106.38	116	109	Total	736.79	754	102

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

StowExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary	<u></u>			Melanoma of Sk	<u>in</u>		
Male	2.86	1	NC*	Male	2.31	3	NC*
Female	1.00	0	NC*	Female	1.71	4	NC*
Total	3.86	1	NC*	Total	4.02	7	174

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma				
Male	1.10	2	NC*	Male	0.62	0	NC*	
Female	0.79	2	NC*	Female	0.50	0	NC*	
Total	1.89	4	NC*	Total	1.12	0	NC*	
<u>Breast</u>				Non-Hodgkin('s) Lymphoma				
Male	0.15	0	NC*	Male	2.69	3	NC*	
Female	20.55	24	117	Female	2.10	0	NC*	
Total	20.70	24	116	Total	4.79	3	NC*	
Cervix Uteri				Oral Cavity and Pharynx				
				Male	2.33	0	NC*	
Female	1.22	0	NC*	Female	0.95	2	NC*	
				Total	3.28	2	NC*	
Colon / Rectum				<u>Ovary</u>				
Male	7.26	8	110					
Female	6.24	5	80	Female	2.39	0	NC*	
Total	13.50	13	96					
Esophagus				<u>Pancreas</u>				
Male	1.23	0	NC*	Male	1.31	0	NC*	
Female	0.30	0	NC*	Female	1.14	2	NC*	
Total	1.53	0	NC*	Total	2.46	2	NC*	
Hodgkin's Disease		homa)		<u>Prostate</u>				
Male	0.54	0	NC*	Male	19.82	18	91	
Female	0.39	1	NC*					
Total	0.93	1	NC*					
Kidney and Renal P				Stomach				
Male	2.06	1	NC*	Male	1.28	0	NC*	
Female	1.12	2	NC*	Female	0.67	1	NC*	
Total	3.18	3	NC*	Total	1.96	1	NC*	
<u>Larynx</u>				<u>Testis</u>				
Male	1.20	0	NC*	Male	0.78	0	NC*	
Female	0.27	0	NC*					
Total	1.48	0	NC*					
<u>Leukemia</u>	-		-	<u>Thyroid</u>				
Male	1.55	2	NC*	Male	0.51	0	NC*	
Female	1.14	0	NC*	Female	1.26	2	NC*	
Total	2.69	2	NC*	Total	1.76	2	NC*	
Liver and Intrahepa		_		Uteri, Corpus and U		_		
Male	0.79	0	NC*					
Female	0.26	0	NC*	Female	3.99	0	NC*	
Total	1.05	0	NC*	Tomaio	0.00	v	110	
Lung and Bronchus		•	.10	All Sites / Types				
Male	9.79	5	51	Male	64.37	44	68 ~-	
Female	7.40	7	95	Female	59.35	52	88	
Total	17.19	12	70	Total	123.71	96	78 #-	
i Ulai	11.13	14	10	i otal	120.7 1	30	10#-	

Obs = observed case count

^{* =} SIR and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

[–] indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level

~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

 \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

SturbridgeExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Ехр	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary				Melanoma of Skin			
Male	5.31	5	94	Male	3.64	2	NC*
Female	1.86	1	NC*	Female	2.66	4	NC*
Total	7.17	6	84	Total	6.31	6	95
Brain and Other Cent	tral Nervous S	<u>System</u>		Multiple Myeloma			
Male	1.64	0	NC*	Male	1.07	1	NC*
Female	1.27	0	NC*	Female	0.87	0	NC*
Total	2.91	0	NC*	Total	1.94	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	<u>nphoma</u>		
Male	0.26	0	NC*	Male	4.35	11	253 #+
Female	32.25	29	90	Female	3.69	4	NC*
Total	32.51	29	89	Total	8.04	15	187 #+
Cervix Uteri				Oral Cavity and Pha			
				Male	3.50	2	NC*
Female	1.83	2	NC*	Female	1.56	1	NC*
		_		Total	5.07	3	NC*
Colon / Rectum				Ovary	0.07	v	110
Male	13.24	10	76	<u>••••</u>			
Female	11.67	23	197 ~ +	Female	3.76	6	160
Total	24.91	33	132	Temale	3.70	O	100
Esophagus	24.51	33	102	Pancreas Pancreas			
<u>Lsopriagus</u> Male	1.98	0	NC*	<u>r ancreas</u> Male	2.27	1	NC*
Female	0.57	0	NC*	Female	2.17	1	NC*
Total	2.55	0	NC*	Total	4.43	2	NC*
			NO		4.43	۷	NC
Hodgkin's Disease (F			NC*	<u>Prostate</u>	22.05	20	0.0
Male	0.78	0	NC*	Male	33.85	29	86
Female	0.61	0	NC*				
Total	1.39	0	NC*	0(
Kidney and Renal Pe		2	NO*	<u>Stomach</u>	0.05	_	000
Male	3.27	3	NC*	Male	2.25	5	222
Female	1.91	2	NC*	Female	1.25	1	NC*
Total .	5.18	5	97	Total	3.50	6	171
<u>Larynx</u>				<u>Testis</u>			
Male	1.88	1	NC*	Male	1.13	1	NC*
Female	0.45	0	NC*				
Total	2.34	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.54	5	197	Male	0.72	0	NC*
Female	1.87	2	NC*	Female	1.86	2	NC*
Total	4.42	7	158	Total	2.59	2	NC*
Liver and Intrahepati	c Bile Ducts			Uteri, Corpus and Ut	terus, NOS		
Male	1.26	1	NC*				
Female	0.48	2	NC*	Female	6.30	7	111
Total	1.74	3	NC*				
Lung and Bronchus				All Sites / Types			
Male	17.16	18	105	Male	109.35	103	94

Female	13.17	7	53	Female	98.98	99	100
Total	30.33	25	82	Total	208.32	202	97

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Sudbury
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

Biadder, Urinary Exp Obs SIR Melanoma of Skir 1 Biadder, Urinary 39 96 Male 7.01 10 18 Female 2.97 3 NC* Female 4.99 9 181 Female 1.23 12 97 Total 12.00 19 188 Brain and Cher Central Nervous System Multiple Myeloms Email Of Cher Central Nervous System Multiple Myeloms Male 3.24 1 NC* Male 1.50 1 NC* Female 2.34 3 NC* Female 1.50 1 NC* Female 6.187 7.2 116 Female 6.29 3 NC* Female 6.187 7.2 115 Female 2.87 2 NC* Female 6.187 7.0 10 NC* NC* NC* NC* NC* NC* NC		Expected a	iiu Obseiveu (Jase Counts, with	ii otaliaalaizea iliciaelice i	Natios, 1999 - 13			
Male Female 9,40 9 96 male Male Female 7,01 mode 10 mode 143 mode Female Female 2,97 3 NC* Female 4,99 9 181 mode Total 12,38 12 97 Total 12,00 19 185 mode Male Nother Central Nervous System Multiple Myeloma Male 3,24 1 NC* Male 1,98 3 NC* Female 2,34 3 NC* Female 1,50 1 NC* Total 5,58 4 NC* Total 3,48 4 NC* Male 0,48 0 NC* Male 6,29 3 NC* Female 61,87 72 116 Female 6.29 3 NC* Female 3,52 2 NC* Female 2,87 2 NC* Female 18,33 11 60 Female 7,16		<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR	
Female Total 2.97 3 NC* Female Total 4.99 9 181 Brain and Other Centrus Veryous System Multiple Myeloma Male 3.24 1 NC* Male 1.98 3 NC* Female 2.34 3 NC* Female 1.50 1 NC* Total 5.58 4 NC* Total 3.48 4 NC* Breast Non-Hodgkin(*s) Lymphom Male 0.48 0 NC* Male 8.20 3 NC* Total 62.36 72 115 Total 14.49 9 62 Eremale 3.52 2 NC* Pemale 2.87 2 NC* Female 3.52 2 NC* Pemale 2.87 2 NC* Female 18.33 15 63 Pemale 7.16 4 NC* Female 18.33 1 60 </td <td>Bladder, Urinary</td> <td></td> <td></td> <td></td> <td>Melanoma of Skin</td> <td></td> <td></td> <td></td>	Bladder, Urinary				Melanoma of Skin				
Total 12.38 12 97 Total 12.00 19 158 Brain and Other Central Nervous System Multiple Myeloma Male 3.24 1 NC* Male 1.50 1 NC* Female 2.34 3 NC* Female 1.50 1 NC* Total 5.58 4 NC* Total 3.48 4 NC* Brail 5.58 4 NC* Mon-Hodgkin(*s) Lymphoma 7 1 NC* Brail 61.87 72 116 Female 6.29 3 NC* Cervix Uteri Dral (20.36) 72 115 Total 14.49 9 62 NC* Female 3.52 2 NC* Female 2.87 2 NC* Female 23.91 15 63 Female 7.16 4 NC* Total 42.24	Male	9.40	9	96	Male	7.01	10	143	
Brain and Other Centrel Nervous System Multiple Myeloma Male 3.24 1 NC* Male 1.98 3 NC* Female 2.34 3 NC* Female 1.58 4 NC* Total 5.58 4 NC* Total 3.48 4 NC* Brain 0.48 0 NC* Male 8.20 6 73 Female 61.87 72 116 Female 6.29 3 NC* Female 62.36 72 115 Total 14.99 9 62 Cervix Uteri Drain 1.00 NC* Female 3.52 2 NC* Female 2.87 2 NC* Female 3.52 2 NC* Female 2.87 2 NC* Male 8.33 11 60 Female 7.16 4 NC* <td cols<="" td=""><td>Female</td><td>2.97</td><td>3</td><td>NC*</td><td>Female</td><td>4.99</td><td>9</td><td>181</td></td>	<td>Female</td> <td>2.97</td> <td>3</td> <td>NC*</td> <td>Female</td> <td>4.99</td> <td>9</td> <td>181</td>	Female	2.97	3	NC*	Female	4.99	9	181
Male Female Pemale P	Total	12.38	12	97	Total	12.00	19	158	
Female Total 2.34 3 NC* NC* Female Total 3.48 4 NC* NC* Breast Non-Hodgkin('s) Lymphoma Male 0.48 0 NC* Male 8.20 6 73 Female 61.87 72 116 Female 6.29 3 NC* Total 62.36 72 115 Total 14.49 9 62 Cervix Uteri Male 7.10 0 NC* Female 3.52 2 NC* Female 2.87 2 NC* Female 3.52 2 NC* Female 2.87 2 NC* Female 3.52 2 NC* Female 2.87 2 NC* Female 3.52 3 NC* Female 7.16 4 NC* Female 18.33 11 60 Female 7.16 4 NC* <th< td=""><td>Brain and Other Ce</td><td>ntral Nervous S</td><td><u>System</u></td><td></td><td>Multiple Myeloma</td><td></td><td></td><td></td></th<>	Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma				
Total 5.58 4 NC* Total 3.48 4 NC* Bereast Non-Hodgkin('s) Lymboma Male 0.48 0 NC* Male 8.20 6 73 Female 61.87 72 116 Female 6.29 3 NC* Total 16.236 72 115 Total 14.49 9 6 73 Cervix Uteri Male 7.10 0 NC* Female 3.52 2 NC* Female 2.87 2 NC* Female 3.52 2 NC* Female 2.87 2 NC* Female 3.52 2 NC* Female 2.87 2 NC* Female 3.52 15 63 Female 2.87 2 NC* Female 18.33 11 NC* Male 4.25 6	Male	3.24	1	NC*	Male	1.98	3	NC*	
Male Male 0.48 0 NC* Male 8.20 6 73 Female Female 61.87 72 116 Female Female 6.29 3 NC* Total 62.36 72 115 Total 10tal 14.9 9 62 Cervix Uteri Male 7.10 0 NC* Female 3.52 2 NC* Female 2.87 2 NC* NC* Female 23.91 15 63 ST NC*	Female	2.34	3	NC*	Female	1.50	1	NC*	
Male Female 0.48 0.87 NC* Pemale Male Female 8.20 6.29 3 NC*	Total	5.58	4	NC*	Total	3.48	4	NC*	
Female Total 61.87 72 (2) 116 (2) Female Total (2) 62.9 (2) 3 (2) NC* (2) Cervix Uteri Total (3) 14.49 (2) 9 (2) 62.2 (2) NC* (2) Male (3) 7.10 (3) NC* (3) NC	<u>Breast</u>				Non-Hodgkin('s) Lyı	<u>mphoma</u>			
Total 62.36 72 115 Total 14.49 9 62 Cervix Uteri Oral Cavity and Pharyxx Female 3.52 2 NC* Female 2.87 2 NC* Female 3.52 2 NC* Female 2.87 2 NC* Colon / Rectum Ovary Male 23.91 15 63 5 63 7.16 4 NC* Female 18.33 11 60 Female 7.16 4 NC* Total 42.24 26 62 #- Female 7.16 4 NC* Bongass 3 NC* Male 4.25 6 141	Male	0.48	0	NC*	Male	8.20	6	73	
Cervix Uteri Oral Cavity and Pharms Female 3.52 2 NC* Female 2.87 2 NC* Female 2.87 2 NC* Colon / Rectum Ovary Male 23.91 15 63 Female 7.16 4 NC* Female 18.33 11 60 Female 7.16 4 NC* Total 42.24 26 62#- Pemale 7.16 4 NC* Male 3.91 1 NC* Male 4.25 6 141 Female 0.89 3 NC* Female 3.47 6 173 Hodgkin's Disease (bulkin burburbur) Prostate Prostate 8 87 Female 1.08 2 NC* Male 66.50 58 87 Female 1.08 2 NC* Male 4.11 4 NC* Female<	Female	61.87	72	116	Female	6.29	3	NC*	
Female 3.52 2 NC* Female 2.87 2 NC* Colon / Rectum Covary Male 23.91 15 63 Female 7.16 4 NC* Total 42.24 26 62 #- Female 7.16 4 NC* Esophagus Pancreas Male 3.91 1 NC* Male 4.25 6 141 Female 0.89 3 NC* Female 3.47 6 173 Total 4.80 4 NC* Total 7.72 12 155 Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 1.50 0 NC* Male 66.50 58 87 Female 1.08 2 NC* Male 66.50 58 87 Female 1.08 2 NC* Male 4.11 4 NC* Female 3.44 </td <td>Total</td> <td>62.36</td> <td>72</td> <td>115</td> <td>Total</td> <td>14.49</td> <td>9</td> <td>62</td>	Total	62.36	72	115	Total	14.49	9	62	
Female 3.52 2 NC* Female 2.87 2 NC* Colon / Rectum Ovary Male 23.91 15 63 Female 18.33 11 60 Female 7.16 4 NC* Total 42.24 26 62 #- ————————————————————————————————————	Cervix Uteri				_	<u>rynx</u>			
Total 9.96 2 NC* Colon / Rectum Ovary Colon / Rectum Dount Colon / Rectum Colo					Male	7.10	0	NC*	
Colon / Rectum Ovary Male 23.91 15 63 Female 18.33 11 60 Female 7.16 4 NC* Total 42.24 26 62 #- Female 7.16 4 NC* Male 3.91 1 NC* Male 4.25 6 141 Female 0.89 3 NC* Female 3.47 6 173 Total 4.80 4 NC* Total 7.72 12 155 Hodgkin's Disease (Hodgkin Lymphoma) Prostate Female 66.50 58 87 Female 1.08 2 NC* Male 66.50 58 87 Female 1.08 2 NC* Male 6.50 58 87 Kidney and Renal Pelvis Stomach Stomach 4 NC* Male 4.11 4 NC* Female 3.44 2 NC* Femal	Female	3.52	2	NC*	Female	2.87		NC*	
Male 23.91 15 63 Female 18.33 11 60 Female 7.16 4 NC* Total 42.24 26 62 #- Female 7.16 4 NC* Male 3.91 1 NC* Male 4.25 6 141 Female 0.89 3 NC* Female 3.47 6 173 Total 4.80 4 NC* Total 7.72 12 155 Hodgkin's Disease (Hodgkin Lymphoma) Prostate Prostate 8 87 Male 1.50 0 NC* Male 66.50 58 87 Female 1.08 2 NC* Male 4.11 4 NC* Kidney and Renal Pelvis Stomach Stomach 1 NC* Female 3.44 2 NC* Female 1.96 1 NC* Total 9.80 6 1 <th< td=""><td></td><td></td><td></td><td></td><td>Total</td><td>9.96</td><td>2</td><td>NC*</td></th<>					Total	9.96	2	NC*	
Female Total 18.33 11 60 Female Total 7.16 4 NC* Esophagus Pancreas Male 3.91 1 NC* Male 4.25 6 141 Female 0.89 3 NC* Female 3.47 6 173 Total 4.80 4 NC* Total 7.72 12 155 Hodgkin's Disease (Hodgkin Lymphoms) Prostate Male 1.50 0 NC* Male 66.50 58 87 Female 1.08 2 NC* Male 66.50 58 87 Kidney and Renal Pelvis Stomach Kidney and Renal Pelvis NC* Male 4.11 4 NC* Female 3.44 2 NC* Female 1.96 1 NC* Total 9.80 6 6 7 7 2 1 NC* F	Colon / Rectum				<u>Ovary</u>				
Total 42.24 26 62 #- Esophagus Pancreas Male 3.91 1 NC* Male 6.89 3 NC* Female 7.72 6 173 141 Female 0.89 3 NC* Female 3.47 6 173 155 Total 4.80 4 NC* Total 7.72 12 155 155 Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 1.50 0 NC* Male 66.50 58 87 87 Female 1.08 2 NC* NC* NC* Total 2.58 2 NC* NC* Male Adal Pelvis Stomach Male 6.36 4 NC* Male 4.11 4 NC* Female 3.44 2 NC* Female 1.96 1.96 1 NC* Total 9.80 6 61 Total 6.07 5 82 Larynx Testis Male 3.80 2 NC* Male 2.08 1 NC*	Male	23.91	15						
Esophagus Pancreas Male 3.91 1 NC* Male 4.25 6 141 Female 0.89 3 NC* Female 3.47 6 173 Total 4.80 4 NC* Total 7.72 12 155 Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 1.50 0 NC* Male 66.50 58 87 Female 1.08 2 NC* Male 66.50 58 87 Total 2.58 2 NC* Stomach 5 8 87 Kidney and Renal Pelvis Stomach 4 NC* Male 4.11 4 NC* Female 3.44 2 NC* Female 1.96 1 NC* Total 9.80 6 61 Total 6.07 5 82 Larynx Testis Male 3.80 </td <td>Female</td> <td>18.33</td> <td>11</td> <td>60</td> <td>Female</td> <td>7.16</td> <td>4</td> <td>NC*</td>	Female	18.33	11	60	Female	7.16	4	NC*	
Male 3.91 1 NC* Male 4.25 6 141 Female 0.89 3 NC* Female 3.47 6 173 Total 4.80 4 NC* Total 7.72 12 155 Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 1.50 0 NC* Male 66.50 58 87 Female 1.08 2 NC* Male 66.50 58 87 Female 1.08 2 NC* NC* <td>Total</td> <td>42.24</td> <td>26</td> <td>62 #-</td> <td></td> <td></td> <td></td> <td></td>	Total	42.24	26	62 #-					
Female 0.89 3 NC* Female 3.47 6 173 Total 4.80 4 NC* Total 7.72 12 155 Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 1.50 0 NC* Male 66.50 58 87 Female 1.08 2 NC* Male 66.50 58 87 Total 2.58 2 NC* Stomach 5 5 1 NC*	<u>Esophagus</u>				<u>Pancreas</u>				
Total 4.80 4 NC* Total 7.72 12 155 Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 1.50 0 NC* Male 66.50 58 87 Female 1.08 2 NC* Male 6.50 58 87 Kidney and Renal Pelvis Stomach Male 6.36 4 NC* Male 4.11 4 NC* Female 3.44 2 NC* Female 1.96 1 NC* Total 9.80 6 61 Total 6.07 5 82 Larynx Male 3.80 2 NC* Male 2.08 1 NC*	Male						6	141	
Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 1.50 0 NC* Male 66.50 58 87 Female 1.08 2 NC* Female 1.08 2 NC* Female 1.08 <td< td=""><td>Female</td><td></td><td></td><td></td><td></td><td></td><td>6</td><td>173</td></td<>	Female						6	173	
Male 1.50 0 NC* Male 66.50 58 87 Female 1.08 2 NC* <td>Total</td> <td>4.80</td> <td>4</td> <td>NC*</td> <td>Total</td> <td>7.72</td> <td>12</td> <td>155</td>	Total	4.80	4	NC*	Total	7.72	12	155	
Female 1.08 2 NC* Total 2.58 2 NC* Kidney and Renal Pelvis Stomach Male 6.36 4 NC* Male 4.11 4 NC* Female 3.44 2 NC* Female 1.96 1 NC* Total 9.80 6 61 Total 6.07 5 82 Larynx Testis Male 3.80 2 NC* Male 2.08 1 NC*									
Total 2.58 2 NC* Kidney and Renal Pelvis Stomach Male 6.36 4 NC* Male 4.11 4 NC* Female 3.44 2 NC* Female 1.96 1 NC* Total 9.80 6 61 Total 6.07 5 82 Larynx Testis Male 3.80 2 NC* Male 2.08 1 NC*					Male	66.50	58	87	
Kidney and Renal Pelvis Stomach Male 6.36 4 NC* Male 4.11 4 NC* Female 3.44 2 NC* Female 1.96 1 NC* Total 9.80 6 61 Total 6.07 5 82 Larynx Testis Male 3.80 2 NC* Male 2.08 1 NC*									
Male 6.36 4 NC* Male 4.11 4 NC* Female 3.44 2 NC* Female 1.96 1 NC* Total 9.80 6 61 Total 6.07 5 82 Larynx Testis Male 3.80 2 NC* Male 2.08 1 NC*	Total	2.58	2	NC*					
Female 3.44 2 NC* Female 1.96 1 NC* Total 9.80 6 61 Total 6.07 5 82 Larynx Testis Male 3.80 2 NC* Male 2.08 1 NC*	·				<u></u>				
Larynx Total 9.80 6 61 Total 6.07 5 82 Larynx Testis Male 3.80 2 NC* Male 2.08 1 NC*							4		
Larynx Testis Male 3.80 2 NC* Male 2.08 1 NC*							•		
Male 3.80 2 NC* Male 2.08 1 NC*	Total	9.80	6	61	Total	6.07	5	82	
	· · · · · · · · · · · · · · · · · · ·								
Female 0.87 0 NC*					Male	2.08	1	NC*	
	Female	0.87	0	NC*					

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Total	4.66	2	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	4.71	5	106	Male	1.46	2	NC*
Female	3.35	0	NC*	Female	3.57	5	140
Total	8.06	5	62	Total	5.02	7	139
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	2.49	2	NC*				
Female	0.79	0	NC*	Female	12.22	7	57
Total	3.28	2	NC*				
Lung and Bronchus	<u>3</u>			All Sites / Types			
Male	32.44	18	55 ~-	Male	208.00	161	77 ^-
Female	23.14	22	95	Female	178.11	167	94
Total	55.58	40	72 #-	Total	386.12	328	85 ~-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** \leq 0.001 level, as well as at the **p** \leq 0.05 and **p** \leq 0.01 levels

Sunderland
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	1.42	0	NC*	Male	1.18	4	NC*
Female	0.53	0	NC*	Female	0.99	0	NC*
Total	1.95	0	NC*	Total	2.17	4	NC*
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	0.57	0	NC*	Male	0.29	0	NC*
Female	0.45	0	NC*	Female	0.24	1	NC*
Total	1.03	0	NC*	Total	0.53	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>iphoma</u>		
Male	0.07	0	NC*	Male	1.43	3	NC*
Female	10.05	12	119	Female	1.17	1	NC*
Total	10.12	12	119	Total	2.59	4	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	1.00	0	NC*
Female	0.79	0	NC*	Female	0.47	0	NC*
				Total	1.47	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	3.58	3	NC*				
Female	3.36	2	NC*	Female	1.24	1	NC*
Total	6.94	5	72				
Esophagus				<u>Pancreas</u>			
Male	0.52	0	NC*	Male	0.61	2	NC*
Female	0.16	0	NC*	Female	0.61	0	NC*

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Total	0.68	0	NC*	Total	1.22	2	NC*
Hodgkin's Disease (I	Hodgkin Lymph	<u>oma)</u>		Prostate			
Male	0.39	0	NC*	Male	8.57	10	117
Female	0.31	0	NC*				
Total	0.70	0	NC*				
Kidney and Renal Pe	<u>elvis</u>			Stomach			
Male	0.93	0	NC*	Male	0.62	1	NC*
Female	0.56	1	NC*	Female	0.38	1	NC*
Total	1.49	1	NC*	Total	1.00	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.50	0	NC*	Male	0.74	0	NC*
Female	0.12	0	NC*				
Total	0.62	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.80	1	NC*	Male	0.30	0	NC*
Female	0.60	0	NC*	Female	0.88	1	NC*
Total	1.40	1	NC*	Total	1.18	1	NC*
Liver and Intrahepat	ic Bile Ducts			Uteri, Corpus and Ut	erus, NOS		
Male	0.36	0	NC*				
Female	0.14	0	NC*	Female	1.79	2	NC*
Total	0.49	0	NC*				
Lung and Bronchus				All Sites / Types			
Male	4.54	3	NC*	Male	30.68	30	98
Female	3.61	3	NC*	Female	30.57	28	92
Total	8.14	6	74	Total	61.25	58	95

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- ^ indicates statistical significance at the p ≤ 0.001 level, as well as at the p ≤ 0.05 and p ≤ 0.01 levels

Sutton
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	4.32	2	NC*	Male	3.21	3	NC*
Female	1.37	1	NC*	Female	2.28	3	NC*
Total	5.69	3	NC*	Total	5.48	6	109
Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	1.48	3	NC*	Male	0.89	1	NC*
Female	1.09	1	NC*	Female	0.66	4	NC*
Total	2.57	4	NC*	Total	1.55	5	322 #+
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>phoma</u>		
Male	0.21	0	NC*	Male	3.81	4	NC*
Female	26.69	13	49 ~-	Female	2.88	2	NC*
Total	26.90	13	48 ~-	Total	6.69	6	90

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Cervix Uteri				Oral Cavity and Pha	<u>arynx</u>		
				Male	3.13	1	NC*
Female	1.64	1	NC*	Female	1.25	1	NC*
				Total	4.39	2	NC*
Colon / Rectum				<u>Ovary</u>			
Male	10.82	6	55				
Female	8.54	6	70	Female	3.15	2	NC*
Total	19.36	12	62				
Esophagus				<u>Pancreas</u>			
Male	1.70	2	NC*	Male	1.91	2	NC*
Female	0.41	1	NC*	Female	1.58	2	NC*
Total	2.12	3	NC*	Total	3.49	4	NC*
Hodgkin's Disease	(Hodgkin Lympl	homa)		Prostate			
Male	0.75	3	NC*	Male	27.89	21	75
Female	0.56	1	NC*				
Total	1.31	4	NC*				
Kidney and Renal P	<u>Pelvis</u>			Stomach			
Male	2.82	2	NC*	Male	1.90	3	NC*
Female	1.51	2	NC*	Female	0.92	1	NC*
Total	4.33	4	NC*	Total	2.83	4	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.63	2	NC*	Male	1.10	2	NC*
Female	0.36	0	NC*				
Total	1.99	2	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.20	2	NC*	Male	0.68	0	NC*
Female	1.55	3	NC*	Female	1.72	1	NC*
Total	3.75	5	133	Total	2.40	1	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	1.09	0	NC*				
Female	0.36	0	NC*	Female	5.14	6	117
Total	1.45	0	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	14.01	12	86	Male	91.69	74	81
Female	10.02	13	130	Female	79.06	69	87
Total	24.04	25	104	Total	170.74	143	84 #-

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Swampscott

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

<u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Bladder, Urinary</u> <u>Melanoma of Skin</u>

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Male	11.47	10	87	Male	7.26	19	262 ^+
Female	4.54	11	242 #+	Female	5.73	3	NC*
Total	16.01	21	131	Total	12.99	22	169 #+
Brain and Other Ce				Multiple Myeloma			
Male	3.11	2	NC*	Male	2.23	1	NC*
Female	2.68	4	NC*	Female	2.04	4	NC*
Total	5.79	6	104	Total	4.27	5	117
<u>Breast</u>				Non-Hodgkin('s) Ly			
Male	0.53	0	NC*	Male	8.76	4	NC*
Female	70.75	78	110	Female	8.46	7	83
Total	71.28	78	109	Total	17.22	11	64
Cervix Uteri				Oral Cavity and Pha	arynx		
				Male	6.90	0	NC*
Female	3.75	1	NC*	Female	3.53	3	NC*
				Total	10.43	3	NC*
Colon / Rectum				<u>Ovary</u>			
Male	28.31	26	92				
Female	28.51	28	98	Female	8.15	13	160
Total	56.81	54	95				
Esophagus				<u>Pancreas</u>			
Male	4.04	6	148	Male	4.76	6	126
Female	1.39	1	NC*	Female	5.25	4	NC*
Total	5.43	7	129	Total	10.01	10	100
Hodgkin's Disease	(Hodgkin Lympl	<u>homa)</u>		<u>Prostate</u>			
Male	1.41	0	NC*	Male	69.85	96	137 ~+
Female	1.20	1	NC*				
Total	2.61	1	NC*				
Kidney and Renal P	<u>Pelvis</u>			Stomach			
Male	6.56	13	198 #+	Male	4.80	4	NC*
Female	4.31	1	NC*	Female	3.07	4	NC*
Total	10.87	14	129	Total	7.87	8	102
<u>Larynx</u>				<u>Testis</u>			
Male	3.76	2	NC*	Male	1.95	1	NC*
Female	1.00	0	NC*				
Total	4.76	2	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	5.13	4	NC*	Male	1.33	1	NC*
Female	4.20	3	NC*	Female	3.71	2	NC*
Total	9.33	7	75	Total	5.04	3	NC*
Liver and Intrahepa				Uteri, Corpus and U	<u>Iterus, NOS</u>		
Male	2.54	4	NC*				
Female	1.14	1	NC*	Female	13.83	16	116
Total	3.68	5	136				
Lung and Bronchus				All Sites / Types			
Male	35.76	29	81	Male	225.49	246	109
Female	30.01	30	100	Female	223.58	232	104
Total	65.77	59	90	Total	449.07	478	106

Obs = observed case count

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

SwanseaExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	11.77	8	68	Male	7.85	3	NC*
Female	4.36	4	NC*	Female	5.77	1	NC*
Total	16.13	12	74	Total	13.62	4	NC*
Brain and Other Ce	entral Nervous S	<u>System</u>		Multiple Myeloma			
Male	3.46	4	NC*	Male	2.32	4	NC*
Female	2.72	1	NC*	Female	2.01	2	NC*
Total	6.18	5	81	Total	4.33	6	139
<u>Breast</u>				Non-Hodgkin('s) Lyr	<u>nphoma</u>		
Male	0.56	0	NC*	Male	9.41	6	64
Female	71.59	62	87	Female	8.32	5	60
Total	72.15	62	86	Total	17.73	11	62
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	7.51	7	93
Female	3.84	6	156	Female	3.52	2	NC*
				Total	11.03	9	82
Colon / Rectum				<u>Ovary</u>			
Male	29.29	25	85				
Female	27.28	19	70	Female	8.26	7	85
Total	56.57	44	78				
Esophagus				<u>Pancreas</u>			
Male	4.32	4	NC*	Male	4.99	6	120
Female	1.33	2	NC*	Female	5.07	12	237 #+
Total	5.65	6	106	Total	10.05	18	179 #+
Hodgkin's Disease	(Hodgkin Lymp	homa <u>)</u>		<u>Prostate</u>			
Male	1.64	2	NC*	Male	74.53	81	109
Female	1.22	1	NC*				
Total	2.86	3	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	7.03	3	NC*	Male	4.98	4	NC*
Female	4.30	4	NC*	Female	2.92	1	NC*
Total	11.34	7	62	Total	7.90	5	63
<u>Larynx</u>				<u>Testis</u>			
Male	4.07	2	NC*	Male	2.38	2	NC*
Female	1.02	1	NC*				
Total	5.09	3	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	5.46	6	110	Male	1.53	1	NC*
Female	4.15	3	NC*	Female	3.81	1	NC*
Total	9.60	9	94	Total	5.34	2	NC*
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	2.73	2	NC*				
Female	1.11	0	NC*	Female	14.07	11	78

Total	3.84	2	NC*				
Lung and Bronchus	<u> </u>			All Sites / Types			
Male	37.69	39	103	Male	239.31	222	93
Female	29.94	23	77	Female	222.40	174	78 ^-
Total	67.64	62	92	Total	461.71	396	86 ~-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** < 0.001 level, as well as at the **p** < 0.05 and **p** < 0.01 levels

TauntonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	•		,		,		
	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	31.26	29	93	Male	21.11	14	66
Female	13.47	17	126	Female	17.90	14	78
Total	44.73	46	103	Total	39.01	28	72
Brain and Other Ce	entral Nervous S	<u>System</u>		Multiple Myeloma			
Male	9.62	9	94	Male	6.08	8	132
Female	8.52	4	NC*	Female	5.98	8	134
Total	18.14	13	72	Total	12.06	16	133
<u>Breast</u>				Non-Hodgkin('s) Lyr	nphoma		
Male	1.47	1	NC*	Male	25.65	30	117
Female	209.99	240	114 #+	Female	25.61	24	94
Total	211.45	241	114 #+	Total	51.26	54	105
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	19.45	37	190 ^+
Female	12.23	12	98	Female	10.49	11	105
				Total	29.94	48	160 ~+
Colon / Rectum				<u>Ovary</u>			
Male	77.58	81	104				
Female	84.73	83	98	Female	24.63	18	73
Total	162.31	164	101				
Esophagus				<u>Pancreas</u>			
Male	11.12	16	144	Male	13.08	17	130
Female	4.12	3	NC*	Female	15.54	16	103
Total	15.23	19	125	Total	28.62	33	115
Hodgkin's Disease	(Hodgkin Lymp	homa)		<u>Prostate</u>			
Male	5.05	7	139	Male	191.03	174	91
Female	4.31	5	116				
Total	9.36	12	128				
Kidney and Renal F	<u>Pelvis</u>			<u>Stomach</u>			
Male	18.41	19	103	Male	13.19	19	144
Female	12.80	18	141	Female	9.22	8	87

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Total	31.21	37	119	Total	22.42	27	120
<u>Larynx</u>				<u>Testis</u>			
Male	10.40	16	154	Male	7.87	10	127
Female	2.88	3	NC*				
Total	13.28	19	143				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	15.07	16	106	Male	4.30	0	NC*
Female	13.03	14	107	Female	12.58	12	95
Total	28.10	30	107	Total	16.88	12	71
Liver and Intrah	epatic Bile Ducts			Uteri, Corpus and L	<u> Iterus, NOS</u>		
Male	7.13	7	98				
Female	3.39	1	NC*	Female	40.17	32	80
Total	10.52	8	76				
Lung and Brond	<u>chus</u>			All Sites / Types			
Male	98.10	133	136 ^+	Male	630.16	686	109 #+
Female	87.67	103	117	Female	668.61	691	103
Total	185.77	236	127 ^+	Total	1298.77	1377	106 #+

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Templeton

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	4.71	2	NC*	Male	3.26	7	215
Female	1.66	1	NC*	Female	2.27	2	NC*
Total	6.37	3	NC*	Total	5.53	9	163
Brain and Other Cer	<u>ntral Nervous S</u>	<u>ystem</u>		Multiple Myeloma			
Male	1.46	0	NC*	Male	0.95	1	NC*
Female	1.09	4	NC*	Female	0.76	1	NC*
Total	2.54	4	NC*	Total	1.71	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>phoma</u>		
Male	0.23	0	NC*	Male	3.88	5	129
Female	27.44	29	106	Female	3.21	5	156
Total	27.67	29	105	Total	7.09	10	141
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	3.14	1	NC*
Female	1.54	1	NC*	Female	1.35	0	NC*
				Total	4.49	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	11.76	16	136				
Female	10.38	14	135	Female	3.20	4	NC*
Total	22.13	30	136				

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Esophagus				<u>Pancreas</u>			
Male	1.77	1	NC*	Male	2.02	3	NC*
Female	0.51	0	NC*	Female	1.92	3	NC*
Total	2.28	1	NC*	Total	3.94	6	152
Hodgkin's Disease	(Hodgkin Lymph	<u>ioma)</u>		<u>Prostate</u>			
Male	0.70	0	NC*	Male	30.10	22	73
Female	0.52	0	NC*				
Total	1.22	0	NC*				
Kidney and Renal	<u>Pelvis</u>			<u>Stomach</u>			
Male	2.92	1	NC*	Male	2.01	3	NC*
Female	1.65	1	NC*	Female	1.12	3	NC*
Total	4.57	2	NC*	Total	3.13	6	192
<u>Larynx</u>				<u>Testis</u>			
Male	1.68	0	NC*	Male	1.02	0	NC*
Female	0.39	0	NC*				
Total	2.07	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.26	0	NC*	Male	0.65	0	NC*
Female	1.64	2	NC*	Female	1.57	0	NC*
Total	3.89	2	NC*	Total	2.22	0	NC*
Liver and Intrahep	atic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	1.13	0	NC*				
Female	0.42	2	NC*	Female	5.34	7	131
Total	1.55	2	NC*				
Lung and Bronchu	<u>ıs</u>			All Sites / Types			
Male	15.24	17	112	Male	97.31	82	84
Female	11.34	14	123	Female	85.39	103	121
Total	26.59	31	117	Total	182.70	185	101

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

TewksburyExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	16.01	15	94	Male	11.83	8	68
Female	5.69	5	88	Female	8.90	9	101
Total	21.70	20	92	Total	20.73	17	82
Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	5.54	3	NC*	Male	3.25	4	NC*
Female	4.21	3	NC*	Female	2.69	2	NC*
Total	9.75	6	62	Total	5.94	6	101
<u>Breast</u>				Non-Hodgkin('s) Lyn	<u>nphoma</u>		

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Male	0.79	1	NC*	Male	14.12	13	92
Female	104.54	115	110	Female	11.65	14	120
Total	105.33	116	110	Total	25.77	27	105
Cervix Uteri				Oral Cavity and Pha			
				Male	11.23	12	107
Female	6.36	4	NC*	Female	4.99	7	140
				Total	16.22	19	117
Colon / Rectum				<u>Ovary</u>			
Male	40.33	37	92				
Female	35.49	41	116	Female	12.30	16	130
Total	75.82	78	103				
Esophagus				<u>Pancreas</u>			
Male	6.20	6	97	Male	6.99	5	72
Female	1.72	0	NC*	Female	6.61	6	91
Total	7.92	6	76	Total	13.60	11	81
Hodgkin's Disease	(Hodgkin Lymp	homa <u>)</u>		<u>Prostate</u>			
Male	2.95	4	NC*	Male	105.09	105	100
Female	2.18	2	NC*				
Total	5.13	6	117				
Kidney and Renal	<u>Pelvis</u>			Stomach			
Male	10.29	14	136	Male	6.92	9	130
Female	6.04	7	116	Female	3.85	2	NC*
Total	16.33	21	129	Total	10.77	11	102
<u>Larynx</u>				<u>Testis</u>			
Male	5.93	7	118	Male	4.65	4	NC*
Female	1.43	1	NC*				
Total	7.36	8	109				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	8.13	8	98	Male	2.57	4	NC*
Female	6.08	4	NC*	Female	6.62	5	76
Total	14.22	12	84	Total	9.19	9	98
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and L	<u>Jterus, NOS</u>		
Male	4.00	4	NC*				
Female	1.48	3	NC*	Female	20.12	16	80
Total	5.48	7	128				
Lung and Bronchu	<u>ıs</u>			All Sites / Types			
Male	52.80	91	172 ^+	Male	342.50	369	108
Female	40.70	46	113	Female	315.32	331	105
Total	93.50	137	147 ^+	Total	657.82	700	106

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

^{* =} SIR and statistical significance not calculated when **Obs** < 5

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	2.74	1	NC*	Male	1.70	3	NC*
Female	1.29	1	NC*	Female	1.42	2	NC*
Total	4.03	2	NC*	Total	3.12	5	160
Brain and Other Cer	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	0.73	1	NC*	Male	0.53	1	NC*
Female	0.68	1	NC*	Female	0.56	1	NC*
Total	1.41	2	NC*	Total	1.09	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyi	mphoma		
Male	0.13	0	NC*	Male	2.05	3	NC*
Female	17.88	21	117	Female	2.28	0	NC*
Total	18.00	21	117	Total	4.33	3	NC*
Cervix Uteri				Oral Cavity and Pha	rynx		
				Male	1.61	0	NC*
Female	0.87	1	NC*	Female	0.93	1	NC*
				Total	2.54	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	6.78	4	NC*				
Female	8.11	3	NC*	Female	2.04	5	245
Total	14.89	7	47 #-				
Esophagus				<u>Pancreas</u>			
Male	0.96	0	NC*	Male	1.13	0	NC*
Female	0.40	0	NC*	Female	1.49	2	NC*
Total	1.36	0	NC*	Total	2.62	2	NC*
Hodgkin's Disease (homa)		Prostate			
Male	0.32	1	NC*	Male	16.96	23	136
Female	0.28	0	NC*				
Total	0.60	1	NC*				
Kidney and Renal P				Stomach			
Male	1.55	2	NC*	Male	1.13	0	NC*
Female	1.14	0	NC*	Female	0.88	1	NC*
Total	2.69	2	NC*	Total	2.01	1	NC*
<u>Larynx</u>	2.00	_		<u>Testis</u>	2.0.	•	
Male	0.89	0	NC*	Male	0.44	0	NC*
Female	0.26	0	NC*		• • • • • • • • • • • • • • • • • • • •	•	
Total	1.15	0	NC*				
<u>Leukemia</u>	1.10	v	110	Thyroid			
Male	1.21	4	NC*	Male	0.30	0	NC*
Female	1.12	0	NC*	Female	0.84	1	NC*
Total	2.34	4	NC*	Total	1.14	1	NC*
Liver and Intrahepat		7	110	Uteri, Corpus and U			110
Male	0.60	1	NC*	oten, corpus and c	<u>terus, 1400</u>		
Female	0.32	0	NC*	Female	3.51	3	NC*
Total	0.92	1	NC*	i Giliale	0.01	J	140
Lung and Bronchus		Į	140	All Sites / Types			
Male	8.64	2	NC*	Male	53.97	52	96
Female	8.05	7	87	Female	58.85	53	90
Total	16.69	9	54	Total	112.82	105	93
10lai	10.09		J 4	I Ulai	112.02	100	33

Obs = observed case count

- * = SIR and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

TollandExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	0.27	0	NC*	Male	0.17	0	NC*
Female	0.07	0	NC*	Female	0.10	0	NC*
Total	0.34	0	NC*	Total	0.27	0	NC*
Brain and Other Cer	<u>ntral Nervous S</u>	<u>System</u>		Multiple Myeloma			
Male	0.07	0	NC*	Male	0.05	0	NC*
Female	0.05	0	NC*	Female	0.03	0	NC*
Total	0.12	0	NC*	Total	0.09	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>iphoma</u>		
Male	0.01	0	NC*	Male	0.20	1	NC*
Female	1.22	0	NC*	Female	0.14	0	NC*
Total	1.23	0	NC*	Total	0.34	1	NC*
Cervix Uteri				Oral Cavity and Phar	=		
				Male	0.17	0	NC*
Female	0.06	0	NC*	Female	0.06	0	NC*
				Total	0.23	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	0.66	0	NC*				
Female	0.45	2	NC*	Female	0.14	0	NC*
Total	1.11	2	NC*	_			
<u>Esophagus</u>				<u>Pancreas</u>			
Male	0.10	0	NC*	Male	0.11	0	NC*
Female	0.02	0	NC*	Female	0.08	0	NC*
Total	0.12	0	NC*	Total	0.20	0	NC*
Hodgkin's Disease (_		<u>Prostate</u>	4.00		
Male	0.03	0	NC*	Male	1.69	1	NC*
Female	0.02	0	NC*				
Total	0.05	0	NC*	0 ()			
Kidney and Renal Po		4	NO*	<u>Stomach</u>	0.44	0	NO*
Male	0.16	1	NC*	Male	0.11	0	NC*
Female	0.07	0	NC*	Female	0.05	0	NC*
Total	0.23	1	NC*	Total	0.16	0	NC*
<u>Larynx</u>	0.00	٥	NC*	<u>Testis</u>	0.04	0	NC*
Male	0.09	0	NC* NC*	Male	0.04	0	NC*
Female	0.02	0					
Total	0.11	0	NC*	Thursa'd			
<u>Leukemia</u>	0.40	^	NC*	<u>Thyroid</u>	0.03	0	NIC*
Male	0.12 0.07	0	NC*	Male	0.03 0.06	0	NC* NC*
Female		0		Female		0	
Total	0.19	0	NC*	Total	0.10	0	NC*

Liver and Intrahepat	tic Bile Ducts			Uteri, Corpus and Uterus, NOS			
Male	0.06	0	NC*				
Female	0.02	0	NC*	Female	0.24	0	NC*
Total	0.08	0	NC*				
Lung and Bronchus				All Sites / Types			
Male	0.85	0	NC*	Male	5.36	4	NC*
Female	0.51	0	NC*	Female	3.75	2	NC*
Total	1.36	0	NC*	Total	9.11	6	66

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

TopsfieldExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

									
	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR		
Bladder, Urinary				Melanoma of Skin					
Male	4.86	2	NC*	Male	3.16	10	317 ~+		
Female	1.96	1	NC*	Female	2.41	4	NC*		
Total	6.82	3	NC*	Total	5.57	14	251 ~+		
Brain and Other Ce	ntral Nervous S	<u>ystem</u>		Multiple Myeloma					
Male	1.37	0	NC*	Male	0.95	0	NC*		
Female	1.11	3	NC*	Female	0.87	1	NC*		
Total	2.48	3	NC*	Total	1.82	1	NC*		
<u>Breast</u>				Non-Hodgkin('s) Lym	nphoma				
Male	0.23	0	NC*	Male	3.79	3	NC*		
Female	30.25	24	79	Female	3.53	3	NC*		
Total	30.48	24	79	Total	7.32	6	82		
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>				
				Male	3.08	2	NC*		
Female	1.53	0	NC*	Female	1.52	2	NC*		
				Total	4.60	4	NC*		
Colon / Rectum				<u>Ovary</u>					
Male	12.07	4	NC*						
Female	12.22	7	57	Female	3.45	2	NC*		
Total	24.29	11	45 ~-						
Esophagus				<u>Pancreas</u>					
Male	1.79	1	NC*	Male	2.07	0	NC*		
Female	0.60	0	NC*	Female	2.24	2	NC*		
Total	2.38	1	NC*	Total	4.31	2	NC*		
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		Prostate					
Male	0.61	0	NC*	Male	30.73	26	85		
Female	0.47	0	NC*						
Total	1.08	0	NC*						
Kidney and Renal P	<u>elvis</u>			<u>Stomach</u>					

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Male	2.86	2	NC*	Male	2.07	2	NC*
Female	1.82	3	NC*	Female	1.34	1	NC*
Total	4.68	5	107	Total	3.41	3	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.67	1	NC*	Male	0.82	1	NC*
Female	0.42	0	NC*				
Total	2.09	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.21	2	NC*	Male	0.59	0	NC*
Female	1.84	3	NC*	Female	1.49	1	NC*
Total	4.05	5	124	Total	2.08	1	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	1.12	0	NC*				
Female	0.49	0	NC*	Female	5.91	9	152
Total	1.60	0	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	15.43	8	52	Male	97.86	67	68 ~-
Female	12.39	8	65	Female	94.93	75	79 #-
Total	27.82	16	58 #-	Total	192.79	142	74 ^-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} < 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

TownsendExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	3.83	5	130	Male	3.18	3	NC*
Female	1.41	0	NC*	Female	2.56	3	NC*
Total	5.24	5	95	Total	5.75	6	104
Brain and Other C	entral Nervous	<u>System</u>		Multiple Myeloma			
Male	1.56	3	NC*	Male	0.82	0	NC*
Female	1.23	1	NC*	Female	0.69	3	NC*
Total	2.79	4	NC*	Total	1.51	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>iphoma</u>		
Male	0.20	0	NC*	Male	3.76	0	NC*
Female	28.88	28	97	Female	3.08	3	NC*
Total	29.08	28	96	Total	6.84	3	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	3.09	1	NC*
Female	1.92	1	NC*	Female	1.34	4	NC*
				Total	4.43	5	113
Colon / Rectum				<u>Ovary</u>			
Male	9.70	6	62				

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Female	8.78	7	80	Female	3.45	9	261 #+
Total	18.49	13	70				
Esophagus				<u>Pancreas</u>			
Male	1.60	0	NC*	Male	1.75	0	NC*
Female	0.42	0	NC*	Female	1.62	0	NC*
Total	2.03	0	NC*	Total	3.36	0	NC*
Hodgkin's Disease	(Hodgkin Lympl	<u>homa)</u>		<u>Prostate</u>			
Male	0.86	0	NC*	Male	25.44	33	130
Female	0.69	0	NC*				
Total	1.55	0	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	2.74	5	183	Male	1.74	1	NC*
Female	1.60	0	NC*	Female	0.96	0	NC*
Total	4.33	5	115	Total	2.70	1	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.56	0	NC*	Male	1.35	1	NC*
Female	0.38	0	NC*				
Total	1.94	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.18	2	NC*	Male	0.74	1	NC*
Female	1.71	0	NC*	Female	2.06	4	NC*
Total	3.90	2	NC*	Total	2.80	5	179
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	1.05	0	NC*				
Female	0.37	0	NC*	Female	5.46	10	183
Total	1.43	0	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	12.77	8	63	Male	85.78	71	83
Female	10.36	6	58	Female	84.67	84	99
Total	23.13	14	61	Total	170.45	155	91

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

TruroExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	2.24	3	NC*	Male	1.26	0	NC*
Female	0.67	1	NC*	Female	0.75	1	NC*
Total	2.91	4	NC*	Total	2.02	1	NC*
Brain and Other Cen	tral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	0.50	2	NC*	Male	0.42	1	NC*
Female	0.36	1	NC*	Female	0.30	0	NC*

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Total	0.86	3	NC*	Total	0.72	1	NC*	
<u>Breast</u>				Non-Hodgkin('s) Lyr				
Male	0.10	0	NC*	Male	1.54	2	NC*	
Female	9.86	15	152	Female	1.21	1	NC*	
Total	9.96	15	151	Total	2.75	3	NC*	
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>			
				Male	1.19	3	NC*	
Female	0.46	0	NC*	Female	0.50	0	NC*	
				Total	1.69	3	NC*	
Colon / Rectum				<u>Ovary</u>				
Male	5.47	5	91					
Female	4.21	5	119	Female	1.12	1	NC*	
Total	9.68	10	103					
Esophagus				<u>Pancreas</u>				
Male	0.74	0	NC*	Male	0.90	1	NC*	
Female	0.21	0	NC*	Female	0.78	3	NC*	
Total	0.94	0	NC*	Total	1.68	4	NC*	
Hodgkin's Disease (Hodgkin Lymphoma)				<u>Prostate</u>				
Male	0.19	0	NC*	Male	13.09	14	107	
Female	0.14	2	NC*					
Total	0.33	2	NC*					
Kidney and Renal F	<u>Pelvis</u>			<u>Stomach</u>				
Male	1.17	0	NC*	Male	0.91	0	NC*	
Female	0.62	1	NC*	Female	0.44	0	NC*	
Total	1.79	1	NC*	Total	1.36	0	NC*	
<u>Larynx</u>				<u>Testis</u>				
Male	0.67	0	NC*	Male	0.23	0	NC*	
Female	0.15	0	NC*					
Total	0.82	0	NC*					
<u>Leukemia</u>				<u>Thyroid</u>				
Male	0.91	1	NC*	Male	0.20	0	NC*	
Female	0.57	0	NC*	Female	0.43	0	NC*	
Total	1.49	1	NC*	Total	0.63	0	NC*	
Liver and Intrahepa				Uteri, Corpus and Uterus, NOS				
Male	0.45	0	NC*					
Female	0.17	0	NC*	Female	1.98	3	NC*	
Total	0.62	0	NC*					
Lung and Bronchus				All Sites / Types				
Male	6.78	6	89	Male	41.74	45	108	
Female	4.48	1	NC*	Female	31.74	37	117	
Total	11.26	7	62	Total	73.47	82	112	

Obs = observed case count

^{* =} SIR and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \leq 0.05$ level

[~] indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

 $[\]land$ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.05$ and $p \leq 0.01$ levels

TyngsboroughExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	4.10	3	NC*	Male	3.41	3	NC*
Female	1.51	2	NC*	Female	2.72	5	184
Total	5.61	5	89	Total	6.13	8	131
Brain and Other Central Nervous System				Multiple Myeloma			
Male	1.70	2	NC*	Male	0.88	0	NC*
Female	1.31	1	NC*	Female	0.74	0	NC*
Total	3.01	3	NC*	Total	1.62	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyı	<u>mphoma</u>		
Male	0.22	0	NC*	Male	4.03	3	NC*
Female	30.84	25	81	Female	3.31	7	212
Total	31.06	25	80	Total	7.34	10	136
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	3.30	4	NC*
Female	2.03	1	NC*	Female	1.43	1	NC*
				Total	4.74	5	106
Colon / Rectum				<u>Ovary</u>			
Male	10.48	11	105				
Female	9.41	11	117	Female	3.68	7	190
Total	19.89	22	111				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	1.73	1	NC*	Male	1.87	0	NC*
Female	0.45	0	NC*	Female	1.75	1	NC*
Total	2.18	1	NC*	Total	3.62	1	NC*
Hodgkin's Disease (<u>homa)</u>		<u>Prostate</u>			
Male	0.93	1	NC*	Male	28.36	18	63
Female	0.73	0	NC*				
Total	1.66	1	NC*				
Kidney and Renal Pe				<u>Stomach</u>			
Male	2.95	5	169	Male	1.83	5	273
Female	1.72	2	NC*	Female	1.03	0	NC*
Total	4.67	7	150	Total	2.85	5	175
<u>Larynx</u>		•		<u>Testis</u>		,	
Male	1.70	3	NC*	Male	1.47	1	NC*
Female	0.41	2	NC*				
Total	2.11	5	237	- 1			
<u>Leukemia</u>	0.05	^	NO*	<u>Thyroid</u>	0.00	•	NO*
Male	2.35	0	NC*	Male	0.80	0	NC*
Female	1.82	3	NC*	Female	2.17	3	NC*
Total	4.17	3	NC*	Total	2.97	3	NC*
Liver and Intrahepat		4	NO*	Uteri, Corpus and U	terus, NOS		
Male	1.14	1	NC*	Famala	F 06	2	NO*
Female	0.40	2	NC*	Female	5.86	3	NC*
Total	1.54	3	NC*	All Cites / Tomas			
Lung and Bronchus Male	14.12	17	120	<u>All Sites / Types</u> Male	93.66	87	93
	14.12	11	98		93.66	91	
Female				Female			100
Total	25.39	28	110	Total	184.30	178	97

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

TyringhamExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	Obs	SIR	
Bladder, Urinary				Melanoma of Skin				
Male	0.45	0	NC*	Male	0.27	0	NC*	
Female	0.12	0	NC*	Female	0.15	0	NC*	
Total	0.57	0	NC*	Total	0.42	0	NC*	
Brain and Other Cer	ntral Nervous S	<u>System</u>		Multiple Myeloma				
Male	0.11	0	NC*	Male	0.09	0	NC*	
Female	0.07	0	NC*	Female	0.06	0	NC*	
Total	0.18	0	NC*	Total	0.14	0	NC*	
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>phoma</u>			
Male	0.02	0	NC*	Male	0.32	0	NC*	
Female	2.05	2	NC*	Female	0.23	0	NC*	
Total	2.07	2	NC*	Total	0.55	0	NC*	
Cervix Uteri				Oral Cavity and Pharynx				
				Male	0.27	0	NC*	
Female	0.10	0	NC*	Female	0.10	0	NC*	
				Total	0.37	0	NC*	
Colon / Rectum				<u>Ovary</u>				
Male	1.10	1	NC*					
Female	0.76	0	NC*	Female	0.23	0	NC*	
Total	1.86	1	NC*					
Esophagus				<u>Pancreas</u>				
Male	0.16	0	NC*	Male	0.19	0	NC*	
Female	0.04	0	NC*	Female	0.14	0	NC*	
Total	0.20	0	NC*	Total	0.33	0	NC*	
Hodgkin's Disease (Hodgkin Lymp	homa)		<u>Prostate</u>				
Male	0.04	0	NC*	Male	2.85	2	NC*	
Female	0.03	0	NC*					
Total	0.07	0	NC*					
Kidney and Renal P	<u>elvis</u>			<u>Stomach</u>				
Male	0.25	0	NC*	Male	0.19	0	NC*	
Female	0.12	0	NC*	Female	80.0	0	NC*	
Total	0.37	0	NC*	Total	0.27	0	NC*	
<u>Larynx</u>				<u>Testis</u>				
Male	0.15	0	NC*	Male	0.05	0	NC*	
Female	0.03	0	NC*					
Total	0.18	0	NC*					
<u>Leukemia</u>				<u>Thyroid</u>				

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Male	0.19	0	NC*	Male	0.05	0	NC*	
Female	0.11	0	NC*	Female	0.09	0	NC*	
Total	0.30	0	NC*	Total	0.14	0	NC*	
Liver and Intrahepat	tic Bile Ducts			Uteri, Corpus and Uterus, NOS				
Male	0.10	0	NC*					
Female	0.03	0	NC*	Female	0.41	0	NC*	
Total	0.13	0	NC*					
Lung and Bronchus				All Sites / Types				
Male	1.41	0	NC*	Male	8.81	4	NC*	
Female	0.86	0	NC*	Female	6.24	3	NC*	
Total	2.26	0	NC*	Total	15.05	7	47 #-	

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** \leq 0.001 level, as well as at the **p** \leq 0.05 and **p** \leq 0.01 levels

UptonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Ехр	<u>Obs</u>	SIR
Bladder, Urinary	·			Melanoma of Skin	•		
Male	3.04	2	NC*	Male	2.19	2	NC*
Female	1.17	2	NC*	Female	1.65	3	NC*
Total	4.22	4	NC*	Total	3.83	5	130
Brain and Other Central Nervous System			Multiple Myeloma				
Male	1.00	1	NC*	Male	0.62	0	NC*
Female	0.80	2	NC*	Female	0.54	1	NC*
Total	1.80	3	NC*	Total	1.16	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Male	0.15	0	NC*	Male	2.60	1	NC*
Female	19.63	16	81	Female	2.29	3	NC*
Total	19.78	16	81	Total	4.89	4	NC*
Cervix Uteri				Oral Cavity and Phar	<u>rynx</u>		
				Male	2.12	3	NC*
Female	1.13	0	NC*	Female	0.96	1	NC*
				Total	3.08	4	NC*
Colon / Rectum				<u>Ovary</u>			
Male	7.63	9	118				
Female	7.38	16	217 ~+	Female	2.30	1	NC*
Total	15.01	25	167 #+				
Esophagus				<u>Pancreas</u>			
Male	1.18	1	NC*	Male	1.32	1	NC*
Female	0.36	0	NC*	Female	1.35	0	NC*
Total	1.53	1	NC*	Total	2.68	1	NC*
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		Prostate			
Male	0.49	2	NC*	Male	19.82	13	66

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	0.39	0	NC*				
Total	0.88	2	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	1.95	2	NC*	Male	1.31	2	NC*
Female	1.17	1	NC*	Female	0.80	1	NC*
Total	3.12	3	NC*	Total	2.11	3	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.13	1	NC*	Male	0.72	0	NC*
Female	0.27	0	NC*				
Total	1.40	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	1.51	2	NC*	Male	0.45	0	NC*
Female	1.20	1	NC*	Female	1.16	1	NC*
Total	2.71	3	NC*	Total	1.61	1	NC*
Liver and Intrahepat	tic Bile Ducts			Uteri, Corpus and Uterus, NOS			
Male	0.75	0	NC*				
Female	0.30	1	NC*	Female	3.79	1	NC*
Total	1.05	1	NC*				
Lung and Bronchus	<u>.</u>			All Sites / Types			
Male	9.98	10	100	Male	64.20	56	87
Female	7.93	7	88	Female	60.95	59	97
Total	17.91	17	95	Total	125.15	115	92

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** \leq 0.001 level, as well as at the **p** \leq 0.05 and **p** \leq 0.01 levels

Uxbridge
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	6.72	6	89	Male	4.68	2	NC*
Female	2.73	0	NC*	Female	3.80	0	NC*
Total	9.45	6	64	Total	8.48	2	NC*
Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	2.15	2	NC*	Male	1.33	0	NC*
Female	1.83	2	NC*	Female	1.23	2	NC*
Total	3.98	4	NC*	Total	2.56	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Male	0.32	0	NC*	Male	5.65	8	142
Female	44.48	36	81	Female	5.29	3	NC*
Total	44.81	36	80	Total	10.94	11	101
Cervix Uteri				Oral Cavity and Phar	<u>rynx</u>		
				Male	4.40	5	114
Female	2.62	2	NC*	Female	2.20	2	NC*

^{* =} SIR and statistical significance not calculated when **Obs** < 5

				Total	6.60	7	106
Colon / Rectum				<u>Ovary</u>			
Male	16.73	10	60				
Female	17.13	18	105	Female	5.23	7	134
Total	33.86	28	83				
Esophagus				<u>Pancreas</u>			
Male	2.48	0	NC*	Male	2.86	2	NC*
Female	0.83	0	NC*	Female	3.15	6	191
Total	3.31	0	NC*	Total	6.01	8	133
Hodgkin's Disease	(Hodgkin Lymph	<u>noma)</u>		<u>Prostate</u>			
Male	1.11	0	NC*	Male	41.90	32	76
Female	0.93	1	NC*				
Total	2.04	1	NC*				
Kidney and Renal P	<u>'elvis</u>			Stomach			
Male	4.09	5	122	Male	2.88	3	NC*
Female	2.67	2	NC*	Female	1.87	4	NC*
Total	6.76	7	103	Total	4.75	7	148
<u>Larynx</u>				<u>Testis</u>			
Male	2.33	0	NC*	Male	1.71	1	NC*
Female	0.61	1	NC*				
Total	2.94	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	3.30	5	151	Male	0.97	0	NC*
Female	2.76	0	NC*	Female	2.71	2	NC*
Total	6.07	5	82	Total	3.68	2	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	1.59	2	NC*				
Female	0.69	0	NC*	Female	8.52	8	94
Total	2.28	2	NC*				
Lung and Bronchus	<u>3</u>			All Sites / Types			
Male	21.33	20	94	Male	137.89	114	83 #-
Female	18.10	19	105	Female	139.54	125	90
Total	39.43	39	99	Total	277.44	239	86 #-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5